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Brightness correction for live cell imaging: The Incucyte S3 (Essen 
Biosystems) automatically adjusts image brightness to maintain white 
balance, with no option to manually fix the relevant settings. In order 
to compensate for this automated adjustment of images, brightfield 
micrographs were re-scaled so that the background was consistent 
between images. This adjustment was necessary for the volume 
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evaluation in figure 3. Here, upper images show original brightfield 
and lower images show adjustments made using an automated script 
in Python 3. These corrected images were used for analysis in figure 




Comparison of control conditions: Overlapping conditions from 
different experiments were compared according to cell passage 
number. All assays shown used 1 μl of fibrin with 1000 fibroblasts 
and plasminogen added at 24 hours, with no additional stimuli. 
Respective conditions come from IPF therapeutic comparison in 
figure 5 (IPF p5), TGF-β1 response in figure 4 (NHLF p3), NHLF 
therapeutic comparison in figure 5 (NHLF p5), cell number effect in 
figure 4 (NHLF p6), plasminogen timing in figure 2 (NHLF p12P), 
and volume consistency in figure 3 (NHLF p12V). Passage numbers 
were compared by time-course pixel intensity (a) and time to 50% 






Description of Supplemental Video 1 - Fibrinolysis: This video 
demonstrates degradation of fibroblast-laden fibrin scaffolds with 
plasmin and plasminogen added at 24 hours. With active plasmin, the 
matrix degrades almost immediately; however, plasminogen is 
delayed due to the necessity for plasminogen to be activated by 
cellular activity. Graphs below each micrograph illustrate changes in 
average pixel intensity as determined by our automated image 






Area validation and time-course pixel intensity: (a) In order to 
validate the automated output from the assay mask generator, final 
assay sizes were compared between the automated image processing 
approach and ImageJ. This comparison showed no significant 
differences between alternate determinations of final contracted assay 
area. (b) Leading up to contraction, image brightness within the 
masked region was evaluated for different TGF-β1 concentrations. 
While initial slopes appeared similar between conditions, the lines for 





Multi-step contraction and double sigmoid fit: Many conditions with 
higher concentrations of TGF-β1 or serum contracted in a multi-step 
process. (a) The single sigmoid had relatively low R2 values, so an 
alternative approach (b) using a double sigmoid was used for 







Serum concentration and seeding density effects: (a, b) Time-course 
changes in assay area show the effects on assay contraction of FBS 
concentration on the left and fibroblast seeding density on the right. 
Fitting of sigmoidal functions to each experimental replicate enabled 
extraction of 50% contraction time (in days) (c, f) and maximum slope 
(d, g). Note that the disparity between apparent slope and maximum 
slope for 8% serum (a, d) is detailed in Appendix Figure A-5. (e, h) 
Final contracted area was also determined for each condition, shown 





Consistency in response between cell lines: (a, b) Histologic sections 
show final contracted assays for NHLF B and IPF B with picrosirius 
red staining. For each example, color brightfield images are shown on 
the left with fluorescent images on the right. Scale bars are 250μm. 
Time-course changes in assay area show the effects of cell line 
variability on assay contraction with no TGF-β1 (c) and with 2 ng/ml 
TGF-β1 (d). Dotted lines indicate conditions with the IPF therapeutic 
nintedanib. (e, f) Final contracted area was also determined for each 





Response to therapeutic stimuli: (a, b) Time-course changes in assay 
area show the effects of various therapeutic stimuli on NHLF (left) 
and IPF fibroblasts (right) in the absence of TGF-β1. (c, d) Parallel 
conditions to the upper graphs show the effects of these therapeutics 
with addition of 2 ng/ml TGF-β1. (e, f) Final contracted area was also 
determined for each condition, indicated in mm2. (Statistical 





Description of Supplemental Video 2 – ECM Remodeling: This video 
demonstrates altered remodeling of fibroblast laden fibrin scaffolds 
with different concentrations of TGF-β1. Higher concentrations result 
in delayed contraction and larger final size of the contracted matrix. 
Graphs below each micrograph demonstrate the image processing 
output of area masks for each time point. Micrographs were taken by 
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 In fibrotic disease, dysregulation of matrix remodeling generates excessive 
deposition of fibrous extracellular protein that can interfere with the architecture and 
function of tissue. The pathogenic role of aberrant fibrin remodeling is particularly 
interesting in idiopathic pulmonary fibrosis (IPF), which has proven largely unresponsive 
to conventional anti-fibrosis therapies. Due to the substantial variety of factors that 
combinatorially influence extracellular matrix (ECM) turnover, there exists the need for a 
phenotypic assay to evaluate cumulative effects involving cell-mediated fibrinolysis and 
collagen deposition. The goal of this project was to develop a novel in vitro assay that 
mimics fibroblast-mediated remodeling of the provisional fibrin matrix, in order to 
establish a model system for fibrotic scar formation and evaluate potential therapeutic 
compounds. 
This work introduces and evaluates new methods to analyze ECM turnover in a 
high-throughput, label-free format. An aqueous two-phase printing technique was 
established to enable generation of microscale fibroblast-laden fibrin gels, which resemble 
the provisional fibrin matrix in wound healing. In a first variant of the assay, addition of 
exogenous plasminogen enabled cell-mediated activation of plasmin for gradual 
degradation of the fibrin matrix. While this assay for cell-mediated fibrinolysis effectively 
demonstrated the effects of pro-fibrotic stimuli on fibrin degradation rates, it showed no 
significant changes in cellular activity with established IPF therapeutics. 
A second variation of the assay implemented higher fibroblast seeding densities 
with serum-supplemented media to facilitate remodeling of the fibrin matrix through 
 xviii 
concurrent fibrinolysis and collagen deposition. Live-cell imaging provided time-course 
brightfield micrographs that were analyzed through an automated image processing 
protocol for high-throughput evaluation of different stages of remodeling. Stimulation of 
assays with IPF therapeutics demonstrated decreased formation of fibrosis. Application of 
this assay allowed convenient evaluation of normal and diseased donors of pulmonary 
fibroblasts and assessment of anti-fibrotic compounds to determine their effects on 
different stages of remodeling. Additionally, the differences in drug response between the 
two variations of fibrin assay indicated that established IPF therapeutics affect fibrotic 
remodeling through mechanisms unrelated to fibrin degradation. 
This analysis of fibroblast-mediated remodeling of fibrin demonstrated 
characteristics of fibrotic ECM remodeling that are not assayed in other in vitro models of 
fibrosis. By investigating the cumulative effects of fibrinolysis and collagen deposition on 
fibroblastic remodeling of fibrin, this assay may provide a new resource for advancing 






CHAPTER 1. INTRODUCTION 
The pathogenesis of fibrosis follows the same sequence of steps and utilizes the same 
biological machinery as healthy wound healing; however, in fibroproliferative disease, 
aberrant regulation of remodeling results in excessive accumulation of ECM. Current 
phenotypic assays for fibrotic activity focus on specific stages of fibrosis pathogenesis such 
as invasion or contraction. There are currently no phenotypic assays to broadly evaluate 
cumulative effects of fibrinolysis and ECM deposition on aberrant matrix remodeling. 
1.1 Research Objectives and Specific Aims 
This work introduces and evaluates a new method to analyze ECM turnover in a 
high-throughput, label-free format. An aqueous two-phase system (ATPS) is used to enable 
generation of microscale fibroblast-laden fibrin gels, which resemble the provisional ECM 
in wound healing. Fibroblasts carry out fibrinolysis, collagen deposition, and matrix 
contraction to remodel the matrix from fibrin into collagen and eventually contracted 
tissue. Compared to other in vitro fibrosis assays, this enables evaluation of a broader range 
of the steps contributing to pathogenesis. By establishing a microscale fibrosis assay that 
enables label free analysis of fibrinolysis and collagen deposition, this technique hopes to 
enable more sophisticated studies of fibrosis biology and fibrosis therapeutics than prior in 
vitro approaches.  
Aim 1: Establish method for micro-printing fibroblast laden fibrin scaffolds. The first 
stage of this project focused on establishing a new technique to offer improved control over 
enzymatic crosslinking of fibrin. This was accomplished by implementing ATPS to 
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maintain fibrinogen and thrombin in separate phases until after the cell laden monomer 
solution had been dispensed. The optimization of a PEG/dextran ATPS enabled successful 
polymerization of sub-microliter volumes of cell-laden fibrin scaffolds, and improved 
control over crosslinking facilitated printing of scaffolds using standard multichannel 
pipettes in 96-well format. This novel fibrin printing approach enabled precise microscale 
control over hydrogel volume to create unprecedentedly small cell-laden fibrin scaffolds. 
Aim 2: Implement fibroblast laden fibrin micro-scaffolds to evaluate cell-mediated 
fibrinolysis. The ATPS fibrin micro-printing approach was then utilized to develop an 
assay for cell-mediated fibrin degradation. Fibrin micro-scaffolds could be directly 
degraded through addition of plasmin, or fibrinolysis could occur through cell-mediated 
activation of exogenous plasminogen. A simple image processing approach was 
established to evaluate fibrinolysis, and fibroblasts were shown to degrade fibrin at a rate 
dependent on cell type, cell density, and the presence of soluble factors. This presented a 
novel approach to evaluate the multifactorial contributions to dysregulated fibrinolysis 
seen in fibrotic disease. 
Aim 3: Establish fibrin remodeling assay & evaluate fibroblasts from normal and 
diseased donors with anti-fibrosis therapeutics. In order to broadly evaluate fibrotic 
remodeling another adaptation of ATPS fibrin micro-printing was implemented; where the 
combination of serum supplemented media, higher cell seeding density, and omission of 
exogenous plasminogen supported concurrent fibrinolysis and collagen deposition. A more 
sophisticated image processing approach from the prior aim was implemented in order to 
evaluate additional remodeling steps, and pro-fibrotic stimuli were evaluated for their 




Figure 1: Generalized steps of wound healing and fibrosis, whereby initial tissue 
injury resolves to restore functional tissue (or deposit fibrotic lesions in fibrosis) 
and diseased lung fibroblasts were utilized in order to evaluate consistency in response to 
therapeutic stimuli and investigate the interplay between fibrinolysis and collagen 
deposition. 
1.2 Wound Healing and Fibrosis 
Wound healing requires a coherent progression of interconnected steps to restore 
functional tissue. The process of wound healing is divided into multiple phases, which are 
labelled in  
Figure 1 as clot formation, inflammation, proliferation, and remodeling [1]. After 
initial injury, the coagulation cascade establishes a fibrin clot to temporarily fill the 
wounded site. During the inflammatory phase, immune cells infiltrate the wound to prevent 
infection and orchestrate the recruitment fibroblasts. Next is the proliferative phase, where 
remodeling of the temporary fibrin matrix into collagen-dense ECM occurs [1]. Finally, 
during the remodeling phase, a more organized matrix resembling native ECM begins to 
restore healthy tissue function [1]. Dysregulation of this healing response can result in  
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Figure 2: Elasticity and compliance of lung tissue are vital for maintaining effective 
gas exchange. When interstitial fibrosis interferes with the mechanical properties of 
the lungs, respiratory capacity gas exchange efficiency can decrease. 
chronic wounds from inadequate ECM deposition or fibrotic scarring from excessive 
deposition. A substantial number of pathways contribute to this matrix turnover, and 
dysregulation can stem from a variety of sources  [2]. In the lungs, matrix properties are 
particularly important due to biomechanical requirements for elasticity and compliance as 
illustrated in Figure 2.  Alterations in lung architecture, such as excessive interstitial 
deposition of ECM, can reduce the efficacy of gas exchange leading to severe pathological 
conditions such as pulmonary fibrosis [3]. Specific matrix alterations and contributing 
biochemical pathways are detailed in the following sections. 
1.3 Pulmonary Extracellular Matrix and Cell Matrix Interactions 
ECM composition of the lungs plays a key role in defining the organ’s physical and 
mechanical properties. The basement membrane in the airways consists of several ECM 
proteins including collagen type IV, laminin, fibronectin, and entactin; all of which are 
involved in regulating the diffusion of gases across the epithelial layer. Pulmonary 
interstitial ECM also modulates a variety of cellular functions including cell migration, 
proliferation, and differentiation [4]. Thus, ECM proteins play essential roles in normal 
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lung structure and function. Although there are several ECM components in the lung, this 
thesis will focus on fibrin and collagen due to their pronounced roles in fibrotic remodeling. 
Fibrillar collagens are synthesized by fibroblasts in a process that is carefully 
regulated to maintain a balance between collagen synthesis and degradation. During 
pathological fibrotic remodeling, the collagen synthesis outpaces degradation and results 
in accumulation. Chemical signaling, biomechanical feedback, and cell-matrix interactions 
all contribute to maintaining this balance between synthesis and degradation [5]. The 
pulmonary ECM interacts dynamically with its surrounding cells, activating a variety of 
signaling pathways which influence cell morphology and behavior. 
Cells are able to utilize the ECM for communication between cells through 
mechanotransduction. Integrins are the surface proteins responsible for these cell matrix 
interactions, and are able to mediate both cell-cell and cell-matrix interactions [6]. In 
addition to direct interaction with ECM protein, integrins also interact with the pro-fibrotic 
cytokine transforming growth factor beta I (TGF-β1), enabling the activation of 
downstream signaling pathways that can increase expression of ECM proteins and ECM 
remodeling. Abnormal integrin signaling and elevated TGF-β1 levels have been implicated 
in pathogenesis of pulmonary fibrosis [7]. 
Degradation activity in ECM remodeling is dependent on numerous mediators 
including cytokines, proteases, growth factors, mechanical forces, and lipid mediators. 
Collagens are primarily degraded by matrix metalloproteinases (MMPs), while fibrinolysis 
is predominantly mediated by the serine proteinases tissue plasminogen activator (tPA), 
urokinase plasminogen activator (uPA), and plasmin [8]. The dominant inhibitor of cell- 
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Figure 3: Wound remodeling relies on coordinated fibrin degradation and collagen 
deposition. 
mediated fibrinolysis is plasminogen activator inhibitor type 1 (PAI-1), which has been 
observed in high levels in various forms of fibrosis [9, 10].  Maintaining a proper balance 
between fibrinolysis and collagen deposition is vital to wound remodeling (Figure 3). 
1.4 Myofibroblasts 
Fibroblasts are generally identified as collagen-producing cells that can anchor to the 
ECM; however, myofibroblasts are more synthetic and can anchor with more contractile 
stress than fibroblasts. These features enable the myofibroblast’s key wound-healing roles 
in collagen production and matrix contraction. During healthy wound healing, fibroblasts 
differentiate into myofibroblasts and generate contractile forces through the expression of 
alpha smooth muscle actin (αSMA). They also produce various ECM proteins for 
remodeling of the damaged tissue [11]. In pathological pro-fibrotic conditions, 
myofibroblasts can persist and sustain excessive production of ECM components. This 
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excessive remodeling can disrupt tissue architecture and function [12]. During fibrosis, 
local fibroblasts are a major source of myofibroblastic cells. However, myofibroblasts may 
develop from other resident cellular precursors including alveolar epithelial cells and bone 
marrow-derived fibrocytes [13, 14]. 
1.5 Idiopathic Pulmonary Fibrosis 
Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative disease with 
no known cause or cure, which effects an estimated 1 in 2000 people [15]. IPF occurs in 
aged demographics, and is diagnosed by histologic determination of usual interstitial 
pneumonia with no known underlying cause. In diagnostic CT scans and histologic sections 
from biopsied lung tissue, IPF is identified by presence of a variety of features including 
honeycombing, fibroblastic foci, excessive collagen accumulation, and loss of alveolar 
epithelial cells [16, 17]. Fibrotic scarring in the lungs not only disrupts the natural elasticity 
necessary for respiration, it also impairs gas exchange through thickening of alveolar walls 
[18]. Although there are two FDA-approved drugs on the market to treat IPF, neither is 
able to effectively halt or reverse disease progression [19]. The following chapter 
elaborates on current progress in developing phenotypic models of pulmonary fibrosis. 
Applications of these models are focused on evaluating fibrosis biology and establishing 





CHAPTER 2. BIOFABRICATION OF PHENOTYPIC 
PULMONARY FIBROSIS ASSAYS* 
 Biofabrication techniques have enabled the formation of complex models of many 
biological tissues. We present a framework to contextualize biofabrication techniques 
within a disease modeling application. Fibrosis is a progressive disease interfering with 
tissue structure and function, which stems from an aberrant wound healing response. 
Epithelial injury and clot formation lead to fibroblast invasion and activation, followed by 
contraction and remodeling of the extracellular matrix. These stages have healthy wound 
healing variants in addition to the pathogenic analogs that are seen in fibrosis. This chapter 
evaluates biofabrication of a variety of phenotypic cell-based fibrosis assays. By 
recapitulating different contributors to fibrosis, these assays are able to evaluate 
biochemical pathways and therapeutic candidates for specific stages of fibrosis 
pathogenesis. Biofabrication of these culture models may enable phenotypic screening for 
improved understanding of fibrosis biology as well as improved screening of anti-fibrotic 
therapeutics.  
2.1 Introduction  
The field of biofabrication, the generation of complex structures from cellular and 
tissue building blocks, has seen widespread growth. These techniques may be useful in a 
wide variety of applications, including tissue engineering and regenerative medicine [20, 
21], developmental biology, disease modeling, drug/toxicity screening models, and others. 
Much attention has been paid to the manufacturing aspect of biofabrication [22], but we 
                                                 
* This chapter has been reproduced from Yamanishi, Robinson, Takayama. Biofabrication of phenotypic 
pulmonary fibrosis assays. Biofabrication, 2019. 11(3)  
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focus here on a framework to consider and evaluate the application of biofabrication to 
disease modeling and drug screening. The design parameters for a biofabricated structure 
should consider the disease pathology, cellular composition, and structure. With cellular 
systems, unexpected structures and functions may arise in interesting ways [23]. As these 
systems are explored and better understood, application to disease pathology is critical for 
translation to effective drug screening. In this chapter, we will focus on biofabrication 
techniques in the context of generating phenotypic assays of idiopathic pulmonary fibrosis. 
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease, in which normal 
lung parenchyma is progressively replaced with fibrotic scar tissue. An estimated 45% of 
deaths in the U.S. are attributed to disorders that are characterized by varying degrees of 
fibrosis, with a rising incidence [24]. Although the pathology of IPF is varied and still 
controversial, it generally involves dysregulation of the normal wound healing process. In 
a prevailing disease theory [25-28], an initial insult to the alveolar epithelial layer leads to 
recruitment of macrophages and other immune cells in a pro-inflammatory response 
(Figure 4). The epithelial injury leads to clotting and fibrin formation, accompanied by 
fibroblast invasion to plug the wound. The fibroblasts then proliferate and activate. 
Activated fibroblasts, termed myofibroblasts due to the expression of alpha-smooth muscle 
actin, contract the tissue and deposit extracellular matrix (ECM) to close the wound. In a 
healthy response, the myofibroblasts would subsequently apoptose to be cleared by 
macrophages, facilitating re-epithelialization and a return to the original healthy state. In 
pulmonary fibrosis, however, the myofibroblasts become senescent [29] and continue to 
generate stiff tissue. Lung stiffening is accompanied by irreversible alveolar collapse, 
ultimately preventing breathing in patients [30].  
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Figure 4. Simplified model of pulmonary fibrosis: Epithelial injury precedes formation of 
the clot-like provisional ECM. Fibroblasts invasion and differentiation accelerates wound closure by 
contracting and depositing ECM. The assays covered in this chapter are listed and roughly sorted by 
the phenotypes present in each assay, labelled by the gray arrows. 
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Treatment options for pulmonary fibrosis are sparse, highlighting the need for 
effective cellular and tissue models of the disease [31]. The standard animal model of 
pulmonary fibrosis uses bleomycin to generate scar tissue in rodents. This model yields 
lungs similar in histological appearance to fibrosis, but subtle differences from the human 
disease have led to misuse of the model [32]. In parallel with animal studies, there has been 
considerable progress in development of complex in vitro models of pulmonary fibrosis 
[33]. A subset of these models provides readouts of cell and tissue level phenotypes 
associated with pulmonary fibrosis. Phenotypic assays are complementary to mechanistic 
assays, because they can account for complex, multifactorial cell behaviors producing 
sometimes unexpected and emergent behavior [34-37]. Phenotypic assays have proven 
generally useful in the discovery of first-in-class therapeutics [38], although not yet for 
fibrosis. Biofabricated phenotypic assays have aided in understanding of disease 
pathology, particularly the role of mechanotransduction and matrix stiffness in a feedback 
loop of fibroblast activation [39-41]. Some of these discoveries have led to the 
investigation of new therapeutic targets [42, 43]. In this chapter, we will examine and 
contrast a variety of biofabrication techniques to assess pulmonary fibrosis phenotypes in 
the in vitro setting. This analysis aims to summarize progress and highlight challenges and 
opportunities in this field. We also note that while this chapter focuses on pulmonary 
fibrosis, many of the concepts are applicable to biofabrication of a broader range of 





Table 1: Biofabricated phenotypic assays for pulmonary fibrosis. Colored dots 
correspond to fibrosis phenotypes, as in Figure 4. ⬤ Epithelial injury and clot formation. ⬤ Fibroblast 
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2.2 Techniques for in vitro phenotypic analysis of pulmonary fibrosis 
This review is organized by describing in vitro cell-based assays that aim to recreate 
various aspects of pulmonary fibrosis pathogenesis roughly in their order of progression in 
vivo: epithelial damage, clotting, fibroblast invasion, fibroblast activation, myofibroblast 
contraction, and myofibroblast persistence. These techniques are summarized in Figure 4, 
where they are sorted roughly by the phenotypes they cover and when those phenotypes 
occur in a simplified model of IPF pathogenesis. Table 1 of this chapter further summarizes 
the techniques.  
2.2.1 Phenotypic assays incorporating epithelial damage 
In the context of pulmonary fibrosis, epithelial damage could arise from a variety 
of sources including aging, smoking, infection, inhaled toxins or nanoparticles, and a 
variety of other insults [74]. A common observation among IPF patients is telomere 
shortening. The telomere shortening hypothesis of disease pathogenesis is consistent with 
the strong correlation between prevalence and patient age. Assays of epithelial damage in 
the context of IPF should therefore include some consideration of aging, repetitive damage, 
or similar types of stress. Downstream biochemical signaling has been reviewed elsewhere 
[3, 75, 76], and should also be considered. A plethora of techniques for culturing and 
assaying epithelial cells exist, but this chapter will cover those assays that pertain most 
specifically to epithelial-fibroblast interactions in pulmonary fibrosis. 
Several techniques have been developed to physically induce epithelial damage, the 
presumed first step towards development of pulmonary fibrosis. Some of these techniques 
use custom-built devices to impose cyclical strain on epithelial cells, similar to that seen in 
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healthy breathing. In one iteration, alveolar epithelial cells were seeded onto a flexible 
silicone membrane, anchored with a washer [45]. This membrane was cyclically stretched 
by pressing on the underside of the membrane with a motorized cam mechanism. The 
authors demonstrated that epithelial cells were damaged by strains of ~25%. Furthermore, 
additional culture time prior to cyclic strain had a protective effect on the epithelial cells. 
Another version of the technique comprised a stretching microdevice with flexible 
polydimethylsiloxane (PDMS) membrane and syringe pump hydraulic actuation [46]. This 
study found that air-liquid interface culture exposed cells to high damage from cyclic 
stretching at ~35% strain. They also examined fluid mechanical stress from liquid plug 
movement, finding that the damage could be reduced by addition of pulmonary surfactant. 
These studies examined physiological strain, but they could be adapted to replicate the 
fibrotic lung, which is less compliant than healthy lungs. Although hyperventilation has 
not been causally linked to pulmonary fibrosis, mechanical ventilation has been shown to 
correlate with bleak outcomes for patients with pulmonary fibrosis whose hypoxemia 
prompts the use of mechanical ventilation [77, 78]. These cyclic stretch models provide 
methods to assess the epithelial contribution to disease exacerbation. 
In static culture settings, membrane culture techniques such as transwell culture 
have gained tremendous popularity. These devices comprise a porous membrane fixed to 
an insert that can be submerged into a culture well, enabling the membrane to physically 
separate co-culture with two distinct cell populations [47]. Transwells have also been used 
extensively to generate and test air-liquid interface (ALI) culture. ALI culture prompts 
many airway epithelial cells to differentiate into more physiologic epithelia [79]. The 
membrane ALI format has been adapted to allow aerosol exposure to nanoparticles in well-
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plate formats [48] as well as microfluidic devices [80]. In addition to cell viability and 
biochemical assays, membrane cultures enable measurement of epithelial barrier integrity. 
Barrier function can be measured by either permeability assays using fluorescently-labeled 
macromolecules, such as dextran [81], or using trans-epithelial electrical resistance [82]. 
Transwell and membrane techniques present versatile tools for biofabrication of assays 
incorporating ALI epithelial components. 
For analysis of epithelial injury and wound healing, the scratch wound assay is well 
established [44]. Briefly, a confluent monolayer of epithelial cells is denuded using a pipet 
tip or other blunt object to tear off the epithelial cells. The remaining edges are tracked 
visually as the epithelial cells proliferate and migrate to repair the wound area. A recent 
paper combined the scratch wound assay with Transwell co-culture [50], wherein A549 
epithelial cells were grown on the top of the membrane, while primary human lung 
fibroblasts (normal vs IPF) were grown on the underside of the membrane, as depicted in 
Figure 2A. The authors reported differing behavior in normal and IPF patient-derived 
pulmonary fibroblasts. After scratching the epithelial layer, the A549 migrated over 4 days 
to close the wound. In co-culture with normal fibroblasts, the fibroblasts migrated into the 
wound site to plug the gap and inhibited re-epithelialization. However, pulmonary fibrosis-
derived fibroblasts failed to invade the wound site, allowing the epithelium to close the 
wound. This study prompts interesting questions about the long-term behavior of 
pulmonary fibroblasts in healthy and diseased states, as the normal fibroblasts appeared 
more active in the short period examined than the diseased fibroblasts, contrary to what 
may be expected.  
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Despite the progress made with biofabricated assays of epithelial damage, there 
remains fertile ground for research regarding long-term culture, chronic epithelial damage, 
and downstream signaling relevant to IPF. A particularly challenging aspect of lung 
research has been the inability to culture alveolar epithelial cells. However, recent work 
has indicated that co-culture with pulmonary fibroblasts may help solve the problem [83]. 
New biofabrication methods could provide additional benefits by working directly with 
clinicians to establish cell cultures directly from the source. 
2.2.2 Phenotypic assays incorporating fibroblast invasion 
Following epithelial damage, a coagulation cascade results in the formation of the 
provisional ECM. Fibrinogen from blood plasma is cross-linked into fibrin, which is 
supported hydrostatically by glycosaminoglycans such as hyaluronic acid [84]. Fibroblasts 
from surrounding tissue then invade this provisional ECM in order to initiate the 
remodeling process. As illustrated in Figure 1, formation of the provisional ECM and 
invasion of fibroblasts is an early component of the wound healing response, where it can 
be exaggerated in fibrotic phenotypes [26]. A number of techniques have been developed 
to recapitulate behavior of fibroblasts in the provisional ECM, both for evaluation of the 
physiology of fibroblast invasion and for screening of potential therapeutics.  
One such approach utilized a fibroblast-containing collagen matrix, formed on top 
of a dehydrated/rehydrated fibrin gel in media. Fibroblasts were then able to invade the 
fibrin matrix. This was used to evaluate the influence of fibronectin during fibroblast 
invasion into a fibrin matrix, and it was found that patterns of fibronectin provide a conduit 
for fibroblast transmigration from collagenous stroma into the fibrin clot provisional  
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Figure 5. Phenotypic assays for invasion: (a) In the Transwell scratch and invasion assay, 
fibroblasts are seeded on the underside of the Transwell, while epithelial cells are seeded on the top 
side. The epithelial layer is gently scratched with a pipet tip to remove a section of epithelial cells. After 
several days of culture, epithelial cells and fibroblasts may migrate into the opened area [50]. (b) The 
collagen plug covered in fibrin assay monitors fibroblast migration from an encapsulated collagen gel 
out into the surrounding fibrin gel [85]. (c) In a spheroid fibroblast invasion assay, spheroids are seeded 
in agarose-coated 384-well microplates. Fibroblasts added after spheroid formation can be observed 
invading the spheroids [56]. 
matrix. Fibroblast migration began as early as 24 hours into the assay, but was significantly 
slowed by the removal of fibronectin [86]. This approach was used to further establish the 
necessity of CD44 and Syndecan-4 Proteoglycan in fibroblast invasiveness [53, 87]. 
Miron-Mendoza et al. used a similar assay to evaluate the differences in fibroblast 
migration through collagen compared to migration through fibrin. Cell-laden collagen 
discs were coated with fibrin for an easily imaged cell invasion assay (Figure 5B). This 
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was used to show that supplemental fibronectin was necessary for the invasive fibroblast 
phenotype, and fibroblast-fibronectin network formation was dependent on α5β1 integrin. 
Fibronectin tracks (fluorescently labelled) were formed at the leading edge of migrating 
cells and fibroblasts preferentially migrated through pre-existing fibronectin tracks laid 
down by other cells [85].  
Other phenotypic assays for fibroblast invasiveness have focused on migration 
from 2D adherent culture into fibrin matrices. One such approach used microdroplets of 
fibroblast suspension patterned on a 6-well plate and covered with a fibrin matrix [88]. 
Through this approach, migration from the 2D culture into the fibrin gel was used to 
evaluate invasiveness of fibroblasts isolated from patients with acute lung injuries. This 
was used to evaluate the role of CD44 in mediating fibroblast invasion and subsequent 
tissue fibrosis. By blocking the function of CD44 with monoclonal antibodies, fibroblast 
invasion into a fibrin matrix was inhibited [54]. 
An alternative, matrix-free approach focused on fibroblast invasion into cancer 
spheroids. This was used for evaluation of therapeutic candidates to combat fibrotic 
processes in cancer, but could be applied as a phenotypic assay for invasiveness in other 
forms of fibrosis. The approach was optimized for 384-well microplates for high-
throughput evaluation of drug libraries. Tumor spheroids were formed in agarose-coated 
wells, as depicted in Figure 5C. A suspension of fluorescently labeled fibroblasts was then 
added and invasiveness was evaluated via confocal spinning disc microscopy to locate the 
fluorescent lung fibroblasts that had invaded the spheroids. A 480-compound library of 
bioactive substances was evaluated for anti-invasiveness, where several prostaglandins and 
ROCK inhibitors were identified as potential therapeutics [56].  
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Lewis et al. used a co-culture technique involving a photodegradable polyethylene 
glycol (PEG)-based hydrogel in order to evaluate the impact of crosstalk between 
fibroblasts and cancer cells on invasiveness of the fibroblasts. An Operetta high content 
imaging machine was used for high-throughput migration tracking in order to show the 
increased invasiveness and matrix metalloproteinase (MMP) expression of fibroblasts 
under the influence of cross-talk with cancer cells compared to fibroblasts alone [49]. 
Despite the involvement of the fibroblast invasion into the provisional ECM during 
fibrosis, there remains a question of whether it is necessary for the pathogenesis of fibrotic 
disease. In the case of pulmonary fibrosis, fibrin deposition does not itself appear to be 
required for pathogenesis because fibrinogen-null mice are still able to develop lung 
fibrosis after bleomycin-induced lung injury [89, 90]. Assays based on fibroblast invasion 
into the provisional ECM should therefore establish physiological importance before being 
used to evaluate compound libraries for potential therapeutic candidates.  
2.2.3 Phenotypic assays incorporating fibroblast contraction 
A histological hallmark of IPF is the presence of fibroblastic foci, dense clusters of 
cells and ECM in the lung. The characteristic cell type in these clusters is the myofibroblast. 
These cells are a differentiated and activated form of fibroblasts, which synthesize high 
amounts of collagen and contract the ECM. The myofibroblast is considered the primary 
effector cell in driving the progression of IPF [91]. There are extensive reviews covering 
the various roles and behaviors of myofibroblasts [91-95]. A plethora of biofabrication 
techniques have been developed to measure contraction, an identifying characteristic of the 
myofibroblast phenotype. The bulk of these techniques are based on collagen contraction, 
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but there are exceptions. Tuan et al. used a fibrin gel scaffold in their model as an analogue 
to the provisional ECM in wound repair. Gel contraction and collagen production were 
evaluated in order to show matrix remodeling under transforming growth factor (TGF-β1) 
stimulation [55]. The use of other hydrogel alternatives to collagen is already covered in 
detail by other reviews [33, 96, 97]. 
2.2.3.1 Collagen gel contraction assay 
Collagen gel contraction is the gold standard of phenotypic readouts for evaluation 
of fibrosis, with widespread use. The first reported use of a collagen gel contraction assay 
established the standard contraction assay format in 1979 [60]. When fibroblast-laden 
collagen gels are cultured in media with serum, they exhibit a high baseline level of 
contraction, shrinking gels to as small as 1/7th the original area within 24 hours [60, 98]. 
The collagen gel may adhere to the walls of the dish, so most protocols physically detach 
the gel from the wall using a sterile pipet tip after polymerization. The need for this step 
limits the throughput of collagen gel contraction assays. These assays are often called 
floating collagen gels [99]. The contraction has been divided into three phases: slow lag 
phase, rapid contraction phase, and sustained slow contraction phase [100]. During the lag 
phase, fibroblasts recover from trypsinization and elongate along collagen fibers. As 
previously reviewed [92], tensile force measurements of collagen gels indicated that the 
lag phase correlates with fibroblast adhesion and cell movement within the collagen gel. 
Therefore, the lag phase has also been called the traction phase [92]. The length of the lag 
phase can be shortened by using more cells, more serum, or cells at higher passage number 
[100]. Following the lag phase, the collagen gel is rapidly contracted and remodeled, at 
rates sped up by high cell number or serum concentration and slowed down by higher initial 
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collagen concentration or cytoskeletal inhibitors. Lastly, the system enters a state of slow, 
prolonged contraction.  
Contraction by fibroblasts is regulated to a large extent by TGF-β1 [101], which 
can be added exogenously to induce contraction [13] or it can be produced or activated by 
fibroblasts themselves [102], among other sources [102-104]. The combination of TGF-β1 
and tensile stress induces fibroblasts to differentiate to myofibroblasts, identified by their 
expression of alpha-smooth muscle actin (α-SMA), stress fibers, and high contractility 
[101]. It should be noted that tensile stress is also a necessary and critical component for 
myofibroblast differentiation [105]. The capacity for tensile stress within collagen gels can 
be increased by tethering gels to the dish [60] or altering gelation parameters to form stiffer 
gels. Gels formed at more acidic conditions down to pH 5.5 have demonstrated higher 
tensile strength than gels formed at more neutral or alkaline conditions up to pH 8.0 [106]. 
Collagen stiffness can also be increased by using higher concentrations of collagen [107].  
Following the initial development of the collagen gel contraction assay, many 
adaptations to the format have been added. The conventional collagen contraction assay is 
low-throughput and high cost, due to the large consumption of collagen and cells. More 
modern techniques enable higher throughput with drastically lower collagen gel volumes. 
In addition to the cost benefit, low volume collagen gels also reduce the diffusion distance 




Figure 6. Collagen contraction adaptations: (a) Soluble, cell-laden collagen is pipeted into glass 
capillary tubes. After gelation, the collagen contracts linearly, enabling easy measurement of 
contraction [62]. (b) Teflon-coated surfaces contain the collagen gel, allowing smooth contraction 
without friction-induced deformations. The mineral oil layer helps confine the gel to the Teflon-coated 
contraction region [64]. (c) Aqueous two-phase systems (ATPS) enable formation of collagen microgels 
without excessive evaporation by confining soluble collagen to a dextran-rich phase until gelation. The 
ATPS components are washed out and floating collagen gel assay can contract [58]. 
One approach to improve assay consistency is to confine the collagen gel within a 
glass capillary tube, yielding a single, linear measurement, as in Figure 6A [62]. Suspended 
human bladder-derived smooth muscle cells in an uncured collagen solution were aspirated 
into glass capillary tubes and polymerized. The collagen gels were then detached from the 
capillary by gently applying air pressure to one end. Over 48 hours of culture, cell viability 
was consistent between the capillary culture method and the traditional whole well culture 
method. Due to the diffusive barrier introduced by the glass capillary, the stimulants and 
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inhibitors were added to the gel prior to polymerization. Standard deviations ran close to 
1% between replicates. The authors also suggest that the capillary technique is amenable 
to future addition of electrical current. Although the capillary technique is limited to short-
term culture applications due to diffusive limitations, it provides a consistent, easy-to-read 
assay that uses low volumes of collagen.  
Although fibroblasts can contract collagen gels shortly after seeding, the gel can often 
attach to the walls and bottom surface of the well, introducing inconsistencies when 
measuring and analyzing the contraction. In addition to the pipet tip manual detachment 
method, several groups have developed techniques to consistently seed gels that cover only 
a fraction of the well area, often employing non-adherent surfaces to further reduce friction 
[61].  
Sage and coworkers published a series of papers using the collagen gel contraction 
assay, with an array of techniques to reduce gel adhesion. They initially used agarose-
coated microwells to reduce the adhesion of the collagen gels to wells [98]. In a subsequent 
study, however, their group designed a water-in-oil system to contain the collagen gel to a 
small Teflon-coated area in the center of the well, as shown in Figure 6B [64]. In this 
technique, a Teflon glass cloth was pinned to the bottom of a 12-well tissue culture well 
with a Teflon-coated washer. The pieces were then submerged in mineral oil. Collagen 
with suspended adult human dermal fibroblasts was then pipetted into the center of the 
Teflon washer ring and incubated to polymerize the gel. Interestingly, the authors found 
that as the collagen gel contracted, it expelled media, leaving a gel in water in oil 3-phase 
system.  The oil and Teflon modified collagen gel contraction assay performed better than 
the conventional assay on multiple fronts. The gels maintained a more consistent circularity 
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compared to the conventional assay, wherein gels had a tendency to adhere to the well and 
form elongated shapes, stretched tightly between the anchor points. In addition to altering 
the gel shape, the anchor points in the conventional method also prevented full contraction, 
introducing noise to the measurements.  
Furthermore, conventional assays exhibited cupping, a result of cells sedimenting 
to the bottom of the collagen gel as it cured, producing vertically asymmetric contraction. 
In the large gels, cupping can interfere with microscopy, as cells in the center of the gel are 
pulled to a higher plane than the cells at the bottom of the well. The pre-warmed oil 
facilitated more rapid polymerization, trapping cells in a more uniformly distributed state. 
In studies using platelet-derived growth factor (PDGF-BB) to stimulate contraction and 
measuring the reduction of area, Sage and coworkers achieved standard deviations of 
roughly 5% between replicates. While the oil and Teflon technique provides a more 
uniform and consistent contraction assay, it does lose some of the mechanical stress that 
has previously been shown to be a driving factor for fibroblast differentiation and activation 
[105]. The authors did not comment on this point. Additionally, the technique is rather low-
throughput and still uses large volume gels. Nonetheless, their study presents a compelling 
case for addressing assay consistency. The widespread availability of non-adherent 
microplates for spheroid culture provide an accessible alternative to the Teflon-coated 
method. 
More recently, aqueous two-phase systems (ATPSs) have been used to generate 
collagen microgels for contraction assays [58] (Figure 6C). Scaling down to single µL gels 
facilitates diffusion of stimulatory or inhibitory proteins and molecules into the center of 
the gel. However, these small gels evaporate during the 30 min collagen polymerization 
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process, often killing the embedded cells. The authors used ATPS to provide an aqueous 
buffer against evaporation, while confining the collagen and cells into the gel during 
polymerization. ATPS are phase separating solutions reminiscent of oil-water two-phase 
systems, but both phases contain primarily water. The distinction between phases in this 
particular ATPS is the presence of immiscible polymers: PEG and dextran. Conveniently, 
many cells and proteins partition preferentially to one phase, allowing ATPS to be used to 
spatially confine cells and collagen. After the collagen gel formed, the PEG and dextran 
were washed out and replaced with culture medium, leaving a 5 µL cell-laden collagen gel. 
This technique is compatible with conventional liquid handling tools and imaging, making 
it appropriate for high-throughput studies. A follow-up study used the technique to produce 
1 µL collagen gels and showed excellent robustness of the technique to assess cytotoxicity 
in collagen gels [59]. However, the consistency and reproducibility of the microgel 
technique to assess contraction have not yet been established. 
Several microfluidic approaches have facilitated formation of sub-millimeter 
collagen gels, as reviewed recently [108, 109]. These techniques use photolithography to 
generate channels 10s to 100s of microns in width for precise and controlled fluid mixing. 
Flow-focusing devices introduce a collagen-containing aqueous phase into a stream of oil 
to produce microdroplets of controlled size [110]. Several groups have utilized these device 
geometries to generate and cure cell-laden collagen microgels 10s to 100s of microns in 
diameter [70, 72, 111]. However, these studies have not yet examined the use of 
microfluidic collagen microgels in contraction assays. 
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2.2.3.2 Mechanics of collagen gel contraction 
In parallel with the development of techniques for assay consistency and throughput, 
several groups have designed methods to measure more detailed mechanical information 
from collagen gel contraction assays. Liu et al. demonstrated the importance of substrate 
stiffness in pulmonary fibrosis by generating a stiffness-gradient collagen gel using 
photopolymerization of polyacrylamide [39]. They showed that fibroblasts are more active 
and responsive to TGF-β1 on stiff substrates and less active on soft substrates. The lack of 
fibroblast activation was also found by inhibiting focal adhesion kinase formation with 
prostaglandin E2, a metabolic product produced by epithelial cells that has also been shown 
to suppress fibroblast activation in co-culture [112]. This technique was demonstrated as 
both a stiffness gradient gel and a 96-well discrete stiffness array, highlighting its 
versatility in probing the contractile phenotype of fibroblasts. It also provided evidence for 
the critical insight that fibroblasts enter a positive feedback loop, activating in response to 
a stiff microenvironment and contracting to exacerbate the stiffness. 
A separate study used agarose to modulate collagen gel stiffness [73]. More agarose 
yields macroscopically stiffer gels, which can activate fibroblasts [39]. However, the 
agarose also reduces the effective local stiffness experienced by the cells, inhibiting the 
ability of the cells to cross-link and locally stiffen the matrix [73]. This study indicated that 
collagen concentration can increase contractility by increasing ligand availability, possibly 
also by reducing the ability of the collagen fibrils to slide past the agarose. The competing 
factors of agarose-to-collagen ratio and the collagen concentration allow fine tuning of both 
collagen stiffness and ligand availability. 
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Although the strength of fibroblast contraction can be inferred in relative terms by 
monitoring the shrinkage of the collagen gel, more granular mechanical information 
requires more advanced techniques. A variety of mechanical sensors and accompanying 
theoretical frameworks have been built into or applied externally to the collagen gels [11, 
113]. Harley et al. made a collagen-glycosaminoglycan scaffold by freeze-drying [114]. 
The process generated somewhat uniform structures with repeating lattice units, allowing 
for single-cell microscopic measurements to be incorporated into a whole-gel solid 
mechanics model. The authors generated both homogeneous, isotropic structures and 
heterogeneous structures for comparison. They used an Euler model of buckling stress to 
determine how much force a cell must exert on the lattice to buckle a strut, given the strut’s 
thickness and the overall elastic modulus of the material. Depending on the thickness of a 
given strut, the dermal fibroblasts exerted contractile stress of 11 to 52 nN per cell. The 
authors examined many individual cells buckling struts of various thicknesses and found 
an upper bound of 450 nN, which the cell was unable to contract. The mode of contractile 
failure was proposed to be at the focal adhesion. While this model provides granular 
information about the mechanical stresses exerted by cells, the collagen 
glycosaminoglycan structure represents a far stiffer matrix (~5 MPa linear elastic modulus) 
compared to the healthy or fibrosis lung (1-20 kPa) [39]. The analysis provided in this 
study could be adapted in future studies examining biofabricated materials with stiffness 
more relevant to pulmonary fibrosis, as well as biochemical stimuli relevant to IPF. 
Another treatment of collagen gel contraction mechanics derived a solid mechanics 
model around a cylindrical collagen disc model [68]. The model assumes an 
incompressible solid with a non-linear strain-dependent elastic modulus. It uses linear 
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elastic mechanics to relate the area reduction and the elastic modulus (measured with a 
nano-indentation probe) to the bulk cell contraction force. These calculations yielded a 
contractile force of 1.41 nN (baseline) to 4.15 nN (activated) per human aortic adventitial 
fibroblast cell. The differences in substrate stiffness and cell type confound any 
comparisons between this method and the collagen-glycosaminoglycan scaffold 
calculations. One drawback to this model is the incompressible solid assumption. Several 
studies cited in this chapter indicate the collagen gels lose water as they compress and 
decrease volume [62, 64], invalidating the incompressible assumption. Nonetheless, this 
model provides a general method to approximate contractile forces from area reduction 
measurements for cylindrical collagen gels. 
2.2.3.3 Strain gauge techniques 
Several techniques have been developed to measure contractile forces using macroscale 
[69] and microscale strain gauges [11]. In most of these systems, cell-laden collagen gels 
are formed to span between two anchors. One or both of these anchors acts as a strain 
gauge. Early methods used large electronic strain gauges, converting the strain (or 
displacement) into a change in resistance using piezoelectric materials [69]. If the geometry 
and elastic modulus of the anchoring material is known, the force exerted by the cells can 
be calculated. Modern methods apply the same principle, but use microscale anchors and 
detect strain by time-lapse imaging. Because the force exerted by cells is relatively small, 
strains on the materials commonly used for cell culture (plastics, PDMS, etc.) can be 
difficult to detect. A common workaround forms the scaffold into tall micropillars, where 
the long torque arm and cantilever action amplifies the distance that the micropillar moves 
in response to the nN-scale cell contractile forces [11].  
 32 
 
Figure 7. Microfabricated devices for fibroblast contraction: (a) Cell-laden collagen gels 
are formed inside of microfabricated, supersoft, donut-shaped wells. The cells are able to contract and 
deform the low elastic modulus pillars [63]. (b) Cell-laden collagen gels are seeded around micropillars. 
When the cells contract, the micropillars bend as predicted by cantilever solid mechanics [52]. 
Another technique to measure the contractile force of fibroblasts used supersoft 
PDMS to generate microposts inside donut-shaped wells, as shown in Figure 7A [63]. 
Although hydrogels and other supersoft materials can be produced, these materials often 
suffer from tearing during demolding in traditional replica molding techniques. The 
supersoft PDMS technique addressed the problem by using ‘hard candy’ recipes to 
generate sacrificial replica molds [63]. This technique enabled fabrication of PDMS 
microwells with 200 µm diameter microposts and an elastic modulus on the order of 0.1 
kPa. Fibroblast-laden collagen gels were centrifuged into the microwells, where they 
formed a ring around the post. When the fibroblasts contracted, they squeezed the post. 
Solid mechanics analysis enabled the calculation of contractile force on the post by 
measuring the reduced post area. The authors reported the force exerted as a bulk radial 
stress and did not calculate a per-cell force. The authors also demonstrated the ability to 
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detect an initial contraction, apply an inhibitor, then see the cells and the post relax back 
toward its original shape, demonstrating reversible elastic compression.  
Chen et al. modified the tethered collagen gel format to work at the microscale, as 
shown in Figure 7B [52]. They tested epithelial cells by treating the cells with multi-walled 
carbon nanotubes (MWCNTs) in the culture flask prior to seeding in the microdevice. Cells 
were then suspended and seeded into the microdevices along with type I collagen by 
centrifugation. The microtissues formed and detached from the outer walls within 12-24 
hours, with cultures lasting for 1 week without detaching from the micropillars, due to their 
goblet shape. The authors found that low concentrations of MWCNTs increased 
contraction force, while high concentrations inhibited contraction force. The low dose 
conditions corresponded to a state of inflammation and activation, indicated by contraction, 
presence of reactive oxygen species (ROS), and miR-21 expression. The high dose caused 
considerable cell death, offsetting the activation, as measured by the contraction force. This 
study demonstrates the need for multifactorial analysis of phenotypic screens, as 
counteracting influences may confound the interpretation of results. In this case, 
measurement of both cell activation (contraction force and ROS production) and cell 
viability elucidated the behavior along a dose-response curve that indicated peak bulk 
pathologic behavior at a medium concentration. 
The same group used a similar approach to evaluate anti-fibrotic therapeutics using 
their in vitro assay [51]. Fibroblasts were suspended by micropillars in a super thin (35 - 
55 μm) collagen layer arranged in a leaflet shape in order to mimic the geometry of alveoli. 
Contractile forces in the collagen were measured by deflection of the micropillars that 
suspended the collagen and differentiation of fibroblasts into myofibroblasts was 
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confirmed by staining for α-SMA. This assay was then used to evaluate the therapeutics 
Nintedanib and Pirfenidone through measurement of both changes in tissue compliance 
and differentiation of fibroblasts into myofibroblasts. They confirmed anti-fibrotic activity 
with both drugs. This paper also used an alternative implementation of the micropillar 
supported collagen membrane to evaluate traction bronchiectasis, a condition involving 
irreversible dilation of bronchi and bronchioles as a result of pulmonary fibrosis. By 
modulating the rigidity of the micropillars, it was shown that increased stiffness in lung 
tissue due to fibrosis would compound lung damage as seen in traction bronchiectasis. 
2.2.3.4 Co-culture collagen gel contraction assays 
The interplay between epithelial cells and fibroblasts may be a key component of 
pulmonary fibrosis pathology [27]. In an early study, A549 or bronchial epithelial cells 
were seeded directly on top of fibroblast-laden collagen gels [65]. Compared to the 
fibroblast monoculture, the co-culture gels showed less total contraction over 15 days. The 
authors fit an exponential decay curve to the area reduction, finding that the co-culture gel 
had the same time constant as the monoculture, despite the differences in total extent of 
contraction. Furthermore, the authors used two-photon microscopy to show that co-culture 
decreased the degree of collagen crosslinking, as inferred by two-photon fluorescence 
intensity. 
In another co-culture study, Ishikawa et al. prepared a similar collagen contraction 
gel with human bronchial epithelial cells seeded directly on top of the gel. However, this 
study also introduced air-liquid interface culture, as depicted in Figure 8 [66]. These gels 
were not manually detached and remained in place for 21 days before stimulation. The gels  
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Figure 8. Direct contact air/liquid interface: Epithelial cells are seeded on top of a fibroblast-
laden collagen gel in a Transwell insert. After confluence is reached, culture media is removed from 
the top well, generating an air-liquid interface culture. The epithelial layer differentiates in response 
to the air-liquid interface. After stimulation, the collagen gel contracts, separating from the walls of 
the well [66]. 
detached by cell contraction when cells were stimulated with TGF-β1. Histology slices of 
the microtissue demonstrated that TGF-β1 also induced a decrease in epithelial layer 
thickness. Immunostaining in these histological slices also revealed changes in MMP and 
tissue inhibitor of metalloproteinase (TIMP) expression due to the crosstalk between co-
cultured cells. These techniques demonstrated the synergistic interactions often seen in co-
culture approaches. 
The biochemical mechanisms of epithelial-fibroblast co-culture have been 
reviewed [75]. Growing evidence indicates that epithelial cells secrete a variety of 
biochemical signals to regulate fibroblast behavior. Biofabrication of phenotypic IPF 
assays would benefit from consideration of this cross-communication. 
2.2.3.5 Alternative techniques to measure fibroblast contraction 
A recently developed technique enables measurement of cell contraction based on 
the cell coverage of the culture surface. The xCELLigence platform uses electrodes 
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patterned on the surface of a culture plate to measure the electrical impedance past the cells 
[67]. As the cells contract, they tighten and narrow, exposing electrode surfaces. The 
exposed surfaces pass current more easily, as the resistance from the cells is removed. One 
of the key benefits of this technique is its rapid response time. However, that may be more 
useful in studies of rapid contraction, as seen in muscle and cardiac tissues rather than the 
progressive contraction typically observed in fibrosis.  
2.2.3.6 Discussion of contraction assays 
As the key effector phenotype of IPF, considerable progress has been made to 
develop biofabrication techniques assessing contraction. However, one key phenotype that 
is missing from these cell-based contraction assays is the divergence between physiological 
contraction, which resolves, and pathophysiological contraction, which persists and 
progresses. The standard collagen gel contraction assay moves only in the direction of 
contraction, with little consideration or potential for reversal. The ability of epithelial cells 
to delay activation and contraction of fibroblasts [66] presents a promising building block 
for future biofabrication of assays that reflect the divergence of healthy contraction 
resolution and pathologic IPF persistence. 
2.2.4 Phenotypic assays incorporating collagen production and deposition 
In addition to collagen contraction, the production and deposition of new collagen 
by fibroblasts is a key event in disease progression. Collagen is produced by multiple cell 
types, but fibroblasts and myofibroblasts are responsible for the increase in collagen 
deposition seen in pulmonary fibrosis. The excessive accumulation of collagen seen in 
fibrosis is a product of both increased collagen production due to changes in transcriptional 
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regulation and decreased degradation modulated by altered expression of various MMPs 
and cathepsins [115]. In order to evaluate the contributions to collagen accumulation, many 
approaches have paralleled the clinical approaches based on staining biopsies and 
evaluating serum biomarkers [116, 117].  Histologic approaches generally utilize sirius red 
and picrosirius red, however these methods lack specificity for collagen types [118]. 
Immunostaining enables identification of specific collagens, however quantification of 
collagen can still be challenging with these approaches. Methods based on soluble 
byproducts of collagen production and degradation have utilized radiolabelled amino acids 
and ELISAs [116, 117]. Other approaches specific to in vitro models have focused on 
evaluation of transcription PCR or electrophoretic mobility shift assay methods [119]. An 
alternative approach to evaluation of collagen remodeling focuses on quantification of 
collagen alignment [120]. Despite the wide array of collagen production assays, few 
biofabrication studies have utilized them. 
A study of kidney mesangial cells in 2D culture indicated that they respond to TGF-
β1 by forming clusters, or nodules, that somewhat resemble the nodules seen in human 
pulmonary fibrosis [57]. Immunostaining of these nodules indicated localized deposition 
of collagen. The nodule assay was later adapted in several different publications, one of 
which used the assay to screen Chinese herbal medicine extracts for inhibition of kidney 
fibroblast nodule formation [121]. Another similar study found that macromolecular 
crowding with dextran sulfate causes much higher collagen deposition by fibroblasts [71]. 
Neutral macromolecular crowding with Ficoll produces less elevated, but more sustained 
collagen deposition with greater cross-linking. Collagen deposition was assessed and 
screened using immunochemical staining and optical microscopy of the cluster formation. 
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This 2D method lacks the complex microenvironment of some of the other techniques, but 
it does provide disease-relevant information by assessing the collagen deposited by the 
fibroblasts. 
In addition to collagen, fibronectin and elastin play substantial roles in pulmonary 
fibrosis. Fibronectin is also an important ECM component that shows increased expression 
in various forms of pulmonary fibrosis [122] and can be quantified by analogous methods 
to those used for collagen. Globular fibronectin in blood serum is integrated in the fibrin 
matrix during formation of the provisional ECM [123] and plays a major role in invasion of 
fibroblasts into the provisional matrix [86]. Fibronectin expression can be up-regulated by 
treatment with TGF-β1 [124]. Fibronectin also binds a large number of growth factors that 
may promote myofibroblast differentiation [125]. Furthermore, a comparison between 2D 
and 3D models of fibroblast adhesion highlighted the importance of 3D scaffolds in 
interactions between fibronectin and integrins [126]. This demonstrates the importance of 
3D biofabricated models in evaluation of ECM remodeling. Elastin is another ECM 
component of interest in pulmonary fibrosis due to its roles in absorption of mechanical 
loads and preventing tissue damage [127]. This role in maintaining elasticity and breaking 
strength in lung tissue makes elastin homeostasis vital in maintenance of lung function. 
However, elastin expression is up-regulated in pulmonary fibrosis, contributing to the 
increased stiffness of fibrotic lung tissue [128]. Due to the importance of ECM composition 
in lung function, future biofabricated phenotypic assays for pulmonary fibrosis may 
consider including evaluation of expression of various ECM components. 
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Figure 9. Healthy function of the lungs: Requires compliant tissue that can readily expand and 
contract in response to diaphragmatic breathing in order to enable gas volume exchange during 
respiration. The line represents the volume of gas inside the lung over time. Normal tidal breathing 
uses a small fraction of the total lung capacity. A full inhale, followed by a full exhale (leaving residual 
gas volume behind) moves a volume of gas equal to the forced vital capacity (FVC). Formation of 
fibrotic foci interferes with this compliance due to the heterogenous accumulation of fibrous connective 
tissue. In the advancement of IPF, both FVC and residual volume progressively decline [129]. Models 
of pulmonary fibrosis could benefit from mimicing alveolar architecture and enabling fibrotic 
remodeling of alveolar tissue. Furthermore, phenotypic evaluation of more clinically relevant metrics 
such as gas volume exchange and tissue compliance may better suit evaluation of anti-fibrotic 
therapeutics. 
2.3 Challenges in biofabrication of pulmonary fibrosis models 
Despite the considerable progress in the field of phenotypic assays, there remains 
opportunity to design microtissues that better capture the complex microenvironment of 
the lung. Specifically, there is a lack of appropriate alveolar models. Existing alveolar 
models typically use artificial substrates to provide the thin membrane structure [130]. 
Although most lung microtissue models use static air or flow-over gas exchange, recent 
work has incorporated more physiologic diaphragmatic breathing [130]. However, these 
models have not been shown to allow the cells to remodel the space, generating healthy or 
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fibrotic tissue. Furthermore, these models generate cell monolayers, lacking the complex 
and interconnected structure of native alveoli, as in Figure 9. This type of architecture and 
cell-driven assembly and construction is a ripe area for the field of biofabrication, 
biomaterials, and bioprinting. In this section, we discuss relevant physiological parameters 
and considerations for adaptation into biofabricated microtissue.  
2.3.1 Suggested design parameters for phenotypic assays of pulmonary fibrosis 
Problems associated with pulmonary fibrosis are predominantly caused by the 
accompanied decline in respiratory function. Excess accumulation of fibrous connective 
tissue interferes with the architecture and function of the lungs, such that gas exchange is 
restricted [131]. This restriction is caused by a number of factors including a decrease in 
number of functional alveoli and an increase in the mechanical stiffness of lung tissue 
[132]. Figure 9 illustrates how fibrotic foci in the lung can interfere with gas exchange at 
the level of individual alveoli. 
To extract biological information from a fibrotic microtissue, the cells should have 
an opportunity to remodel their own microenvironment. Compared to the phenotypic 
assays presented in this chapter, modern biofabrication techniques, such as bioprinting, 
hold additional potential for their ability to use bioactive and degradable bioinks, while still 
establishing complex structures. A major shift in microtissue phenotypic assays would 
examine restoration of function, rather than only measuring therapeutic interventions at the 
point of disease progression/exacerbation.  
To recapitulate the restoration of lung function, consideration of relevant patient-
level measurements may be informative. In patients, overall lung decline is typically 
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measured in four ways: forced vital capacity (FVC - the maximum volume of air that can 
be inhaled and exhaled), carbon monoxide diffusion capacity (DLCO, a measure of gas 
transfer efficiency across the alveolar-capillary membrane), dyspnea (shortness of breath) 
and oxygen saturation after exertion (6-minute walk test). Each of these measurements 
reflect aspects of the total lung decline in pulmonary fibrosis. The FVC reflects a decline 
in compliance and the fraction of volume occupied by gas. Both DLCO and the 6-minute 
walk test assess the ability of the lungs to transfer oxygen species into the blood, while 
dyspnea may reflect an inability to effectively remove carbon dioxide. The reduction in gas 
exchange results from both a thickening of the alveolar wall and the reduction in the 
volume of gas exchanged in a full breath, as indicated by the reduction in FVC. Typical 
values for these measurements are included in Table 2. Incorporation of these patient-level 
measurements to a model would provide more directly relevant phenotypic readouts. 
Table 2: Patient-level phenotypic measurements in IPF. 
Macroscopic 
patient phenotypic 
parameter Description Functions measured Numbers Ref 
Forced vital 
capacity (FVC) 
Max volume of air that can be 










Shortness of breath Gas exchange, 




6-minute walk test.  
The patient is instructed to 
walk for 6 minutes, after which 











Measure of the conductance of 
gas transfer from inspired gas 
to red blood cells 
Gas exchange at the 
blood level 
Lower in IPF [136] 








As biofabricated models of pulmonary fibrosis become more sophisticated, it is 
important to mimic the physiological parameters of both healthy and fibrotic lung tissue, 
particularly with the selection of biomaterials. General guides for selecting biomaterials 
for biofabrication have been published [137-140]. In the lungs, the dominant ECM 
components are collagen IV, laminin, entactin, and proteoglycans in basement membranes; 
and fibrillar collagens, elastic fibers, and proteoglycans in interstitial connective tissue. 
Fibronectin and tenascin are also present in the provisional ECM, which is important 
during development and wound repair [4]. In fibrosis, there is increased expression of 
elastin, fibronectin and collagens I, III, and IV. This alteration in ECM composition 
increases the stiffness of lung tissue, consequently decreasing the lungs’ ability to exchange 
gas [141]. In healthy tissue, alveolar compliance has been measured at 1-5 kPa, while 
fibrotic lung tissue is much stiffer, at 20-100 kPa [142]. 
Cellular composition of lung tissue also changes significantly during the 
pathogenesis of fibrosis. Cells found in the lungs include epithelial cells, endothelial cells, 
interstitial cells, macrophages, fibroblasts, and immune cells among others. These cell 
types are covered in greater detail in prior reviews [143, 144]. As stated previously, 
following epithelial injury, inflammatory cells such as macrophages, neutrophils, and T 
cells migrate to damaged epithelium where they produce a variety of cytokines and 
chemokines that amplify the inflammatory response. This also triggers fibroblast 
recruitment, proliferation, and activation of myofibroblasts [145]. Small aggregates of 
proliferating fibroblasts, myofibroblasts, and immune cells are concentrated in areas 
known as fibrotic foci. These areas are the sites of excessive ECM production where 
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scarring disrupts lung architecture and function [25]. Figure 9 demonstrates the effect that 
fibrotic foci can have on gas exchange function. 
The micro-scale structure of alveoli has been analyzed through a variety of imaging 
methods, including in vivo fluorescence microimaging [146], cryosectioning [147], and 
casting [148]. These measurements converge on alveolar diameter on the order of hundreds 
of microns and alveolar mouth openings that are 85-90% of the alveolar diameter (Figure 
9 and Table 3). Furthermore, many of the gaseous alveolar compartments abut capillaries, 
enabling gas exchange. In healthy patients, this translates to a fractional tissue volume (mL 
tissue to mL of total lung) of 0.106-0.191 between inspiration and expiration [149]. 
However, in fibrotic lungs, the accumulation of tissue increases the fractional tissue 
volume to 0.220-0.345 [149]. In the diseased state, fibroblast foci generate local alveolar 
collapse [150], making measurements of individual alveolar geometry difficult. Accurately 
designed micro-alveolar tissues should approximate these ratios of gas to tissue in order to 
reflect the altered microenvironment between healthy and diseased states.  
Table 3: Selected physical properties of the lung. 
Property Values in healthy people Values in IPF patients 
Compliance 1-5 kPa [142]  20-100 kPa [142]  
Fractional tissue 
volume  
(mL tissue per mL 
tissue and gas)  
0.106 – 0.191 (inspiration - expiration) [149] 0.220 – 0.345 [149] 
Alveolar mouth 
opening 278 μm [146] 291.4 μm [151] 
Alveolar depth to 
mouth diameter 
0.85-0.9 for residual capacity to total lung capacity. 0.95-1.5 below 
residual capacity – results in collapse [147] NA 
Alveolar half-opening 
angle  60 degrees [148, 152] NA 
Alveolar lining layer 
thickness  0.1-0.2 μm [152, 153]  NA 
Alveolar diameter 225 μm [154] NA 
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The use of exogenous biomaterials, such as polymers, can augment mechanical 
properties [39] or structure [51, 52, 63] of biofabricated models [137]. However, these 
exogenous materials can disrupt local mechanical properties in often unexpected ways 
[73], in addition to potential questions of cytotoxicity. Nonetheless, the interplay between 
exogenous and native biomaterials may produce interesting discoveries and further inform 
biofabrication of future models. 
2.3.3 Bioprinting techniques 
The choice of biofabrication technique may pose additional constraints on the 
selection of biomaterials. The technique of 3D bioprinting remains poorly explored in the 
area of fibrosis assays, but the general field of bioprinting has been reviewed extensively. 
A recent review of bioinks elaborated on several approaches to print fibroblast-laden 
hydrogels, however none of these methods were used to evaluate fibrosis [155]. Another 
review covering 3D bioprinting techniques evaluated bioprinting for creation of complex 
3D biomimetic architectures to provide improved in vitro analogues to in vivo tissue 
organization [156]. Decellularized ECM bioprinting techniques provide additional 
promise, as they already include native architecture [157]. These various techniques could 
be utilized to provide an added level of sophistication to fibrosis assays in order to evaluate 





2.4 Conclusions and future directions 
Considerable progress has been made in the past two decades to biofabricate 
complex 3D lung culture environments that recreate aspects of pulmonary fibrosis 
pathogenesis. These encompass epithelial damage, fibroblast invasion, contraction, and 
ECM deposition. Furthermore, some of these techniques have been adapted and applied as 
medium-throughput phenotypic screens for potential therapeutics.  
However, there remains unexplored territory, particularly in the areas of alveolar 
architecture, provisional extracellular matrix and long-term disease progression. These 
areas present particularly challenging hurdles for cell-based assays. Clotting is a complex 
process involving many different factors from blood. Incorporation of endothelial 
compartments or fibrin assays has somewhat addressed the issue. Recent literature 
implicates aging and fibroblast senescence as key differences between fibrotic and healthy 
tissue in both animal models [158] and in human patients [159]. The role of senescence in 
fibrosis has been reviewed recently [29]. Maintaining long-term culture has proven 
difficult, although multicellular systems have shown some success, including the direct 
contact epithelial-fibroblast culture that lasted 21 days [66]. Furthermore, we have 
deliberately neglected the ever-present immune system in this chapter. The exact role of 
the immune system in IPF remains controversial and the challenges surrounding 
biofabrication of immune components are immense, but new work in this area could have 
tremendous benefits. 
Development of future phenotypic assays should carefully consider the unique 
features of the lung environment: mechanical compliance, tissue geometry, and the 
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composition of cells and matrix proteins. Furthermore, selection of appropriate readouts 
will be critical to answering the right questions about disease progression. If the assays are 
to be adapted to high-throughput screens, then extensive optimization of the reproducibility 
and performance of the assay should be performed. Biofabrication of culture models that 
enable phenotypic screening of pulmonary fibrosis presents a compelling approach to 
finding new therapies in pulmonary fibrosis and potentially other related aberrant wound 
healing diseases.  
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CHAPTER 3. AQUEOUS TWO-PHASE PRINTING AND 
FIBRINOLYSIS OF FIBROBLAST-LADEN FIBRIN MICRO-
SCAFFOLDS† 
 This chapter describes printing of microscale fibroblast-laden matrices using an 
aqueous two-phase approach that controls thrombin-mediated enzymatic crosslinking of 
fibrin. Optimization of aqueous two-phase formulations enabled polymerization of 
consistent sub-microliter volumes of cell-laden fibrin. When plasminogen was added to 
these micro-scaffolds, the primary normal human lung fibroblasts converted it to plasmin, 
triggering gradual degradation of the fibrin. Time-lapse live-cell imaging and automated 
image analysis provided readouts of time to degradation of 50% of the scaffold as well as 
maximum degradation rate. The time required for degradation decreased linearly with cell 
number while it increased in a dose-dependent manner upon addition of TGF-β1. 
Fibroblasts isolated from idiopathic pulmonary fibrosis patients showed similar trends with 
regards to response to TGF-β1 stimulation. Addition of hydrogen peroxide slowed 
fibrinolysis but only in the absence of TGF-β1, consistent with the notion that cellular 
phenotypes induced by TGF-β1 are mediated, at least in part, through increased production 
of hydrogen peroxide. FDA-approved and experimental anti-fibrosis drugs were also tested 
for their effects on fibrinolysis rates. Given the central role of fibrinolysis in both normal 
and pathogenic wound healing of various tissues, the high-throughput cell-mediated 
fibrinolysis assay described has broad applicability in the study of many different cell types 
                                                 
† At the time of dissertation submission, this chapter was under review as Robinson, et al. Aqueous two-
phase printing and fibrinolysis of fibroblast-laden fibrin micro-scaffolds. Biofabrication, xxxx. 
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and diseases. Furthermore, aqueous two-phase printing of fibrin addresses several current 
limitations of fibrin bio-inks, indicating additional applications in tissue engineering and 
in vitro models. 
3.1 Introduction 
Degradation of the provisional fibrin matrix is a key process in wound healing [160]. 
Following tissue damage, fibrin serves as a temporary scaffold that enables fibroblasts to 
migrate to the injury site for matrix remodeling [161]. Accelerated fibrin degradation can 
delay healing by hindering cells’ ability to migrate into the wound [3], while suppressed 
fibrin degradation can promote fibrotic scarring by contributing to excessive collagen 
accumulation [162, 163]. Properly regulated fibrinolysis is crucial to wound resolution; 
however, few phenotypic assays are available to evaluate cell-mediated fibrin degradation 
[164]. Due to the variety of cell-produced proteases and inhibitors as well as biomechanical 
cellular processes that combinatorially influence fibrinolysis [165], there exists the need 
for a high-throughput phenotypic assay for cell-mediated fibrin degradation.  
Many techniques to evaluate cell-mediated fibrinolysis focus on quantifying mRNA 
and protein expression for specific components of the fibrinolytic system; however, these 
approaches are liable to overlook the fibrinolytic contributions of any components that are 
not specifically evaluated [166-169]. Cell-mediated modulation of the fibrinolytic system 
occurs predominantly through regulating conversion of the proenzyme plasminogen into 
the active enzyme plasmin, which degrades fibrin into soluble degradation products. This 
activation of plasmin is controlled by cellular expression of a variety of proteases and 
inhibitors, enabling cells to both positively and negatively regulate fibrinolysis [170-174]. 
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Due to this large number of regulators involved in fibrinolysis, experimental approaches 
that focus on specific contributors to cell-mediated fibrin degradation are liable to overlook 
unexpected changes to the fibrinolytic system. 
Here, we analyze human lung fibroblast-mediated fibrinolysis with a focus on 
idiopathic pulmonary fibrosis (IPF), a disorder of unknown etiology where repeated small 
injuries have been suggested to play a role. This chronic fibroproliferative disease presents 
as an exaggerated aging process; where epigenetics, senescence, and biomechanics have 
all been proposed as potential contributing factors [27]. The progression of IPF results in a 
continued decline in lung capacity that ultimately leads to respiratory failure [25]. A 
growing body of evidence indicates that dysregulation of the fibrinolytic system may be a 
contributor to IPF pathogenesis [175-177]. Current FDA-approved drugs for IPF are 
incapable of halting or reversing fibrosis, and can only slow the spread of fibrotic scarring 
throughout the lungs [26]. A high-throughput phenotypic assay for fibrinolysis may 
contribute to efforts to find therapeutic compounds. 
There are currently few phenotypic approaches to evaluate fibrinolysis. One  
implementation of cell-laden fibrin gels was able to differentiate between fibrinolytic 
stimuli and cell source tissue by comparing relative amounts of degraded matrix between 
conditions [164]. Importantly, this approach implemented a fibrin hydrogel, which enabled 
the biophysical feedback of matrix interactions to contribute to fibrin remodeling [178, 
179]. However, this fibrinolysis assay faces limitations due to its large volume format. A 
high-throughput adaptation of this fibrin-based fibrinolysis assay would require 
establishing a microplate-compatible technique to generate the cell-laden fibrin scaffolds. 
This poses an engineering hurdle due to difficulties controlling thrombin-mediated 
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crosslinking for low volume fibrin structures [180]. No prior methods to fabricate 
microscale fibrin scaffolds were suitable for this high-throughput assay. 
To consistently print microscale cell-laden fibrin scaffolds with standard liquid 
handling equipment, this work details a new approach that controls crosslinking during the 
polymerization process by introducing fibrinogen and thrombin within separate aqueous 
phases. We utilize an aqueous two-phase system (ATPS), in which soluble polymers 
thermodynamically drive aqueous systems to form two distinct phases. Our research group 
has previously developed ATPS assays to evaluate collagen contraction with living cells 
[58]. Here, the optimization of a PEG/dextran ATPS enables successful polymerization of 
sub-microliter volumes of cell-laden fibrin scaffolds. These microgels can be directly 
degraded through addition of plasmin, or fibrinolysis can occur through cell-mediated 
activation of exogenous plasminogen. Fibrinolysis rates vary in response to pro-fibrotic 
stimuli and anti-fibrotic therapeutics, as determined through label-free brightfield 
microscopy. We demonstrate our fibrin-printing technology as a simple, versatile, and 
easily managed approach to fabricate precise microscale scaffolds, and this technology was 
applied for high-throughput evaluation of cell-mediated fibrinolysis. 
3.2 Materials and Methods 
3.2.1 Cell culture and ATPS reagents 
A stock solution of DEX (20% w/w dextran T500; Sigma) was prepared in 
phosphate buffered saline (PBS) on a rocker overnight. A stock solution of PEG (6% w/w, 
35k MW; Sigma) was prepared in fully supplemented culture media with 10% deionized 
water to balance osmolality. Both stock solutions were passed through a 0.22 μm sterilizing 
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syringe filter before storage. PEG working solutions were stored for up to 2 weeks at 4C. 
Thrombin (Human Alpha Thrombin; Enzyme Research Labs) was also added to the PEG 
solution at a concentration of 0.1 U/mL immediately preceding experiments. Fibrinogen-
DEX solutions were prepared by diluting fibrinogen stock solution (human fibrinogen 3; 
Enzyme Research Labs) to a final concentration of 4 mg/mL in a sterile solution of 4% 10x 
DMEM, 15% DEX stock solution (to a final concentration of 3% dextran), and 50% cell 
suspension in growth media. For all experiments excluding cell concentration evaluation, 
the cell suspension was diluted for 1000 cells per microliter in the final fibrinogen-DEX 
solution. 
3.2.2 Cell preparation 
Normal human lung fibroblasts (NHLF lot#0000580583; Lonza) from a 79 year old 
female with a history of smoking, and idiopathic pulmonary fibrosis fibroblasts (IPF 
lot#0000627840; Lonza) from a 52 year old male were cultured in fibroblast growth media 
(FGM; Lonza). Cells were passaged at 80-90% confluence, and were sub-cultured in 1:3 
ratios by trypsinization. When at the desired confluence, cells were washed with PBS and 
0.05% trypsin solution was added to the flask. Cells were incubated for 2 min, diluted with 
fibroblast growth media media, and then harvested and centrifuged (200 x g, 5min) in a 
conical tube. The supernatant was aspirated and the cell pellet was re-suspended in serum-
free culture media. When used in fibrin degradation experiments, cells were re-suspended 
at 2x the final desired concentration (1000 cells/μl unless otherwise indicated). All 
experiments were conducted with cells at or below passage 12. In all experiments, media 
was changed every 48 hours and any media additives (plasminogen, TGF-β1, drugs, etc.) 
were included. 
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3.2.3 ATPS printing of fibrin microgels 
Working solutions of PEG with 0.1 U/mL of thrombin were warmed to 37C and 
pipetted into a 96-well plate. For production of droplets, fibrinogen-DEX solutions with 
cell suspension were maintained at 37C and pipetted directly into the PEG-thrombin media 
using either a manual pipette or a semi-automated 96-channel pipette (Viaflo-96; Integra). 
All assays utilized a volume of 1 μl unless otherwise noted. Following dispensing of the 
DEX phase, the plates were placed in an incubator at 37C for 30 min to allow the thrombin 
to enzymatically crosslink the fibrinogen into a fibrin matrix (Figure 10A). The PEG-
enriched media was then washed four times by removing, then replacing half of the media 
with PEG-free media. When applicable, the final media addition was supplemented with 
stimuli as detailed in section 2.5. For the duration of each experiment, assay plates were 
imaged every 2 hours at 4x with an automated cell culture monitoring system (Incucyte S3; 
Essen Biosystems). After one day of culture, plasminogen (50 μg/mL) (Human Glu-
Plasminogen; Enzyme Research Labs) was added as a 10x concentrated solution to each 
well in order to initiate assay degradation (Figure 10B), unless otherwise noted for specific 
conditions. Fresh plasminogen was included with each subsequent media addition. Positive 
controls with active plasmin (1 U/ml) (Human Plasmin; Enzyme Research Labs) and 
negative controls without plasminogen were included in each experiment. As cells 





3.2.4 High-throughput brightfield image analysis 
After each experiment, brightfield images for every time point were downloaded in 
jpeg format from the automated cell culture monitoring system. Python’s OpenCV library 
was implemented for the masking approach illustrated in Figure 11A. First, a threshold was 
set at 50% of the maximum intensity (128 for 8-bit integer pixel values) in order to isolate 
the darker pixels of semi-opaque fibrin hydrogel from the background of the image. A 
closing morphological filter with a 25x25 kernel was then applied to each mask in order to 
remove noise. This masking approach was applied to the initial time point from every 
experimental condition in order to establish the relevant assay area for downstream 
measurements.  As fibrin degrades during an experiment, the average pixel intensity within 
the masked area increases accordingly (Figure 11B). The automated live-cell imager 
(Incucyte S3; Essen Biosystems) automatically adjusts brightness to maintain consistent 
white balance between images. For experiments involving multiple assay volumes, image 
brightness was scaled to maintain consistent background intensity (Appendix Figure A-1).  
For each experimental replicate, a sigmoid curve was fit using the curve_fit 
function from the SciPy library in Python. The logistic function given by the equation in 
Figure 11C enabled automated extraction of the time point for 50% degradation, as well as 
the maximum slope at the equation’s centroid (Figure 11 D, E). 
3.2.5 Phenotypic evaluation of stimuli 
In order to evaluate fibrin degradation rate with a known anti-fibrinolytic stimulus, 
various concentrations of transforming growth factor type β1 (Human Recombinant TGF-
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β1; Peprotech) were added to the assay media after ATPS polymers were rinsed out of the 
microplates. 
To evaluate the capability of this assay to test the fibrinolytic effects of therapeutic stimuli, 
a variety of drug compounds were introduced to the fibrinolysis assays after the wash step. 
This included 40 μM pirfenidone (Selleck Chem), 0.4 μM nintedanib (Selleck Chem), 100 
μM hydrogen peroxide (Sigma), and 20 μM diethyl-pythiDC (AOBIOUS). These 
concentrations were established in preliminary experiments that evaluated a range of 
concentrations used in prior literature. Stimuli were freshly mixed for each media change 
during experiments, and a minimum of four replicates were tested per experimental 
condition. 
3.2.6 Statistical Analysis 
All experimental values are reported as means ± standard deviation. ANOVA tests 
were performed using the statsmodels library in Python 3 with the Tukey test for post-hoc 
pairwise comparisons. 
3.3 Results and Discussion 
The development and characterization of the cell-mediated fibrinolysis assay was 
focused on establishing a microplate-compatible fibroblast-laden fibrin scaffold and 
verifying the ability to distinguish between subtly different fibrinolytic environments. First, 
we implemented an ATPS approach to enable accurate printing of unprecedentedly small 
cell-laden fibrin scaffolds. Then, an automated image processing approach quantified fibrin 
degradation data from label-free brightfield images. Next, the established fibrinolytic  
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Figure 10. ATPS fibrin printing and cell-mediated degradation: (a) Illustration of the 
enzymatic control enabled by ATPS printing of fibrin scaffolds, whereby thrombin from the PEG 
phase diffuses into the dextran phase and crosslinks the fibrinogen into fibrin during the incubation 
period. (b) Process schematic of ATPS generation of microscale fibrin droplets and subsequent 
fibrinolysis. (c) Characteristic brightfield microscope images (taken at 4x magnification) illustrate the 
assay progression when stimulated with 0.5 ng/mL of TGF-β1, showing an opaque fibrin matrix and 
progressive degradation. Scale bars are 1 mm. 
effects of cell density and TGF-β1 were used to validate the assay’s capability to 
distinguish between conditions. Finally, the microscale cell mediated fibrinolysis assay 
was implemented to evaluate the effects of anti-fibrotic therapeutics on fibroblasts from 
normal and diseased donors. 
3.3.1 Fabrication of microscale fibrin scaffolds 
Biological environments establish fibrin matrices through coagulation, where a 
cascade of clotting factors activates thrombin, which enzymatically crosslinks fibrinogen 
into fibrin [161]. Similarly, in vitro fibrin scaffolds rely on exposing monomeric fibrinogen 
to thrombin [181]. Fibrin has been used extensively in a wide variety of tissue engineering 
applications, but it is generally implemented as a bulk cast hydrogel. There have been a 
few applications of fibrin bio-printing that control crosslinking by alternating between 
layers of fibrinogen and thrombin, but this poses limitations to accuracy and reproducibility 
due to lack of control over fibrinogen’s exposure to thrombin [181-183]. There have also 
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been a variety of applications for fibrin microbeads where oil immersions were used to 
disperse microbeads during crosslinking in oil-suspended droplets, but this results in 
inconsistent size and cells must be added separately after the microbeads have been washed 
[184, 185]. Reliable microscale volume and microplate compatibility were necessary to 
enable high-throughput adaptation in this assay. Precise control over cell seeding density 
was also vital for our approach due to its effect on remodeling rate. 
We established a new approach to maintain fibrinogen in a distinct droplet and 
control diffusion of thrombin into fibrinogen during the polymerization process by 
implementing an ATPS with PEG and dextran. Above their critical concentrations, these 
soluble polymers thermo-dynamically drive aqueous systems to form two distinct phases 
[186]. A previous ATPS microscale adaptation from our lab for collagen contraction 
demonstrated consistency in response between the conventional 100 uL assay and ATPS 
microscale volumes. They specifically took advantage of the short length scales for time-
dependent and burst stimulation profiles, which would not be possible with conventional 
approaches due to diffusion constraints [58]. A similar ATPS adaptation suits our 
approach, and enables fabrication of microscale fibrin scaffolds with standard liquid 
handling equipment to facilitate microplate compatibility. 
During the initial optimization of PEG and dextran concentrations, we found that 
lower concentrations were unstable and resulted in fissure of the ATPS droplet. In order to 
maintain stable separation of phases during polymerization, minimum assay concentrations 
of 6% 35 kDa PEG and 3% T500 dextran were determined for stability during crosslinking 
(Figure 10A). Fibroblast viability has previously been verified at these ATPS 
concentrations in a prior microscale assay adaptation [58].  
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The necessity for this ATPS environment in our microscale fibrin degradation assay 
comes from the capability of aqueous two-phase partitioning to control diffusion of 
thrombin into the fibrinogen droplet. This restricts enzymatic crosslinking of cell-laden 
fibrin matrices until after the droplets have been dispensed (Figure 10A). After a 30 minute 
incubation period, the fibrin was sufficiently polymerized and the ATPS solutions could 
be rinsed and replaced with growth media and stimulants for specific conditions (Figure 
10B). We waited an additional period of 24 hours before adding exogenous plasminogen 
to enable cells to anchor themselves to the fibrin matrix. 
After plasminogen is added to the assays, various activators and inhibitors produced 
by cells regulate the conversion of plasminogen into plasmin [170-174]. Control conditions 
for each experiment verified rapid matrix degradation with the addition of exogenous 
plasmin and no matrix degradation when plasminogen is omitted (Supplemental Video 1). 
As the assay proceeds, the fibrin matrix gradually degrades with activated plasmin cleaving 
fibrin into soluble fibrin degradation products (Figure 10C).  This is visually evident as 
disappearance of the opaque fibrin matrix. The following section is focused on 
implementing an image processing and analysis approach in order to automate 
quantification of differences in fibrin degradation between conditions. 
3.3.2 Label-free quantification of fibrin degradation 
In the context of wound healing and fibrosis, evaluation of cell-mediated 
fibrinolysis generally implements quantitative assays to measure specific mRNAs and 
proteins involved in plasmin activation [166-169]. This evaluation is generally limited to 
the proteases that cleave plasminogen into activated plasmin and the inhibitors of these  
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Figure 11. High-throughput quantification of fibrin degradation: (a) Automated image 
processing and analysis utilized Python’s OpenCV library for thresholding and morphological filtering 
in order to establish an initial mask for each individual assay that was applied to all assay images for 
that well. Scale bars are 1 mm. (b) The average pixel intensity within masked regions was plotted for 
time course evaluation, as illustrated here with different plasminogen addition times, where dotted 
lines indicate the plasminogen addition time and error bars represent the standard deviation between 
experimental replicates. (c) An example measurement demonstrates image metric extraction by fitting 
a logistic function to time course pixel intensity data with least squares regression. The time point for 
50% degradation (d) and maximum slope from the sigmoid centroid (e) were determined using logistic 
functions fit for each experimental replicate. Note that the 50% degradation time (vertical axis) is 
indicated here as days after plasminogen addition, while the plasminogen addition time (horizontal 
axis) is in hours. (Statistical significance for (d, e)  P < 0.01 by ANOVA.  ab = P < 0.01;  bc = P < 0.05;  
ac = P < 0.1 by post-hoc Tukey test. N = 5 for all conditions) 
proteases; however, a variety of other enzymes and inhibitors, which are often overlooked, 
are also involved in regulation of cell-mediated fibrinolysis [172, 173]. Here, label-free 
evaluation of live-cell images enables quantification of fibrin degradation. 
Due to the relative opacity of our fibrin scaffolds, pixels within the assay area are 
significantly darker than those in the background of microscope images. This enables an 
analysis approach based on pixel intensities within the assay area.  Many established 
hemostasis assays take advantage of fibrin’s attenuation of light for quantification. These 
assays generally implement plate readers to measure absorbance during coagulation and 
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fibrinolysis [187, 188]. Evaluation of this assay in a microplate reader may therefore serve 
as an alternative to brightfield analysis. However, our approach favored evaluation of pixel 
intensity from brightfield images so that the micrographs could serve as validation of assay 
progression. Unfortunately, the commercial image analysis package embedded in our live 
cell imaging system was not able to reliably discern the microprinted fibrin scaffold. We 
therefore developed an alternative image analysis pipeline using Python’s OpenCV library. 
In order to isolate the assay area from background, a thresholding approach was 
sufficient because of the significant difference in pixel brightness. Here, any pixels brighter 
than the specified threshold were classified as background. A closing morphological filter 
was applied to the thresholded images to remove noise left by the thresholding process. 
Figure 11A demonstrates mask generation and its implementation at later time points as 
the fibrin matrix degrades. After isolation of the assay area, average pixel intensity within 
masked regions was plotted in order to visualize time-course fibrin degradation (Figure 
11B). Fitting time-course data from each individual well with a sigmoidal curve facilitated 
extraction of the time point for 50% matrix degradation, as well as the maximum slope at 
the sigmoid’s centroid (Figure 11C).  
Figure 11D shows changes in the 50% degradation time point in response to 
different plasminogen addition times. The 50% degradation time point is shown as days 
since plasminogen addition. Increases in bar height indicate slower cell-mediated 
fibrinolysis. ANOVA indicated statistical significance of these differences in degradation 
time (P < 0.01), and post-hoc pairwise analysis with the Tukey test demonstrated 
statistically significant differences between specific conditions (Figure 11D). The increase 
in time to 50% degradation for later plasminogen additions indicates significant changes 
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Figure 12. Assay volume consistency: (a) ATPS printing of fibrin scaffolds demonstrated 
consistency in assay shape and texture between volumes. Scale bars are 1 mm. (b) Cross sectional area 
of assays was compared between image J, Python generated masks, and a geometric model of assay 
volume. (c) A doubled spherical cap demonstrated the best fit of the geometric volume models 
evaluated (including sphere, hemisphere, and single spherical cap). (d) Time course data shows 
changes in average pixel intensity for different assay volumes to demonstrate consistency in fibrin 
degradation time between volume conditions. Different initial pixel intensity values between conditions 
indicate varied transmission of light through different volume constructs. The 50% degradation time 
(e) and maximum slope (f) further demonstrate these trends. (Statistical significance for (b, f) P < 0.01 
by ANOVA.  ab = P > 0.2;  cd = P < 0.05 by post-hoc Tukey test. N = 4 for all conditions) 
in the scaffold or cells in the first 24 hours. It has previously been demonstrated that cell-
matrix interactions influence the rate of fibroblast-mediated fibrinolysis, so additional time 
before plasminogen addition may have influenced rates observed here through similar 
pathways [179]. Hence, it was important in subsequent studies to evaluate cell-mediated 
fibrin degradation with a consistent plasminogen addition time. A plasminogen addition 
time at 24 hours was implemented so that fibroblasts could initiate cell-matrix interactions. 
The effects of assay volume were also evaluated. Assay volumes between 0.5 μl 
and 8 μl could be consistently printed and viewed within the field-of-view of a 4x 
microscope objective (Figure 12A). The Python-based image masking approach was 
compared against a manual approach that outlined the assay area in image J with no 
significant differences in cross sectional area between techniques (Figure 12B). Cross 
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sectional area was also compared to volume through evaluation of geometric models. 
Compared against spheres, hemispheres, and spherical caps; a doubled spherical cap fit the 
volume and area data most closely as determined through least squares regression (Figure 
12C).  
In our prior microscale adaptation of collagen contraction, we found that different 
assay volumes maintained consistent contraction rates as long as cell density was 
maintained [58]. Fibrinolysis trends in our experiments also depend on cell density rather 
than assay volume. While the pixel intensity of higher volume assays had lower starting 
values, this reflected the presence of more fibrin which resulted in decreased transmission 
of light through those assays (Figure 12D). Time points for 50% degradation, as determined 
by a sigmoid fit, showed no significant difference in degradation timing between different 
volume conditions (Figure 12E). This consistency in degradation timing indicates similar 
rates of cell-mediated fibrinolysis between different volume conditions. Differences in 
maximum slope between conditions followed the same trend as differences in initial pixel 
intensity, resulting from the decreased transmitted light through higher volume fibrin 
scaffolds. 
The consistency in degradation rates between volume conditions indicates 
uniformity in fibrin organization. Fibrin network morphology has a significant impact on 
fibrinolysis rate, where tight fibrin conformations degrade at a slower rate than scaffolds 
with looser fibrin conformations and thicker fibers [189]. This suggests that at the 
concentration of thrombin used in our assays, ATPS-mediated control over the diffusion 
of thrombin into the fibrinogen-containing phase results in consistent fibrin organization 
across the range of assay volumes tested. 
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Figure 13. Cell density and TGF-β1 effects: (a) Time course pixel intensity data demonstrates 
changes in fibrin degradation between different densities of cells within a 1 μl assay. The 50% 
degradation time (b) and maximum slope (c) demonstrate decreased fibrinolysis time and increased 
slope with higher cell counts. (d) Pixel intensity data for various concentrations of TGF-β1 indicates 
delays in fibrin degradation in response to the stimulus. The 50% degradation time (e) and maximum 
slope (f) show increases in fibrinolysis time but no significant changes in slope with higher 
concentrations of TGF-β1. (Statistical significance P < 0.01 by ANOVA. In (b, c, e, f) P < 0.05 by post-
hoc Tukey test between all bars with different lettered labels. N = 4 for all conditions) 
3.3.3 Effects of cell seeding density and TGF-β1 
Cell seeding density was also evaluated. Conditions with higher seeding densities 
demonstrated significantly faster fibrinolysis (Figure 13), with decreased time points for 
50% degradation and increased maximum slope (Figure 13 B, C; P < 0.05 for all pairwise 
comparisons). The linear relationship between rate of fibrinolysis and cell number is 
consistent with a cell-mediated step being rate limiting in this process. This also highlights 
the importance of consistent cell-seeding density in fibrin printing applications. Our ATPS 
printing technique is uniquely capable of establishing microscale cell-laden fibrin scaffolds 
with a consistent seeding density [181, 185]. 
TGF-β1 is an established pro-fibrotic stimulus with well-characterized anti-
fibrinolytic effects [190]. Various concentrations of TGF-β1 were used to stimulate NHLF 
cells in the fibrin assays (Figure 13D. Increasing concentrations resulted in longer time 
delays before fibrinolysis. The time points for 50% degradation further demonstrate this 
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trend (Figure 13E). All pairwise differences in 50% degradation time between conditions 
were significant with P < 0.05 (Figure 13F). Interestingly, these differences in fibrinolysis 
profile appear as a delay before initiation of fibrin degradation. Prior studies have linked 
elevated PAI-1 with delayed fibrinolysis [191], although additional evaluation is necessary 
to determine its relative contribution to the changes in fibrinolysis rate associated with 
TGF-β1 stimulation [192].  
In NHLF cells, we also noticed an effect of cell passage number on fibrinolysis 
(Appendix Figure A-2a). Higher passage numbers exhibited progressively longer 50% 
degradation times with slower fibrin degradation rates (Appendix Figure A-2b). These 
incidental observations are consistent with prior studies that demonstrate that PAI-1 is 
upregulated in senescent fibroblasts in vivo and in vitro [193-195]. 
3.3.4 Evaluation of hydrogen peroxide, therapeutics and IPF fibroblasts 
Having established baseline cell response measurements for fibrinolysis of the 
bioprinted fibrin micro-scaffolds, we next compared fibrinolytic profiles between normal 
and diseased lung fibroblasts with a number of stimulants and inhibitors. Hydrogen 
peroxide is a reactive oxygen species (ROS) known to be produced by cells in response to 
TGF-β1 stimulation, while nintedanib and pirfenidone are the only two FDA-approved 
therapies for IPF. Diethyl-pythiDC, an experimental anti-fibrotic drug, is an inhibitor of 
certain prolyl 4-hydroxylases that play a role in post-translational modification of collagen 
and other proteins [196]. The plasmin control condition was included in graphs for  
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Figure 14. Cell donor and drug stimulation: Time-course pixel intensity data show the effects 
on fibrin degradation of several different stimulants, with NHLF cells on the left and diseased IPF cells 
on the right. The upper pixel intensity graphs have no TGF-β1 (a and e) while the lower graphs contain 
2 ng/ml TGF-β1 (b and f). Sigmoid fits were used to determine 50% degradation time (c, d, g and h) 
from the above pixel intensity graphs. (Statistical significance P < 0.01 independently for drug and 
TGF-β1 stimulus by two-way ANOVA: As the positive control, plasmin was excluded from ANOVA.  
‡ = P < 0.01;  ad, be = P < 0.05;  ac, fg, fh = P < 0.1 by post-hoc Tukey test. N = 4 for all conditions) 
reference, but was excluded from statistical analysis in the interest of focusing on 
therapeutic conditions of interest. 
A general comparison between normal and diseased fibroblasts (Figure 14 A-H) 
demonstrates that cells from the IPF donor consistently degraded fibrin significantly faster 
than the normal fibroblasts (P < 0.01 by two-way ANOVA). However, prior research 
indicates that diseased fibroblasts from IPF donors express elevated levels of PAI-1 and 
should consequently exhibit slower fibrin degradation [10]. This unexpected decrease in 
fibrinolysis time in IPF fibroblasts may be due to the cells’ extended removal from the 
diseased microenvironment. In the diseased lung, overactive epithelial cells secrete several 
growth factors, cytokines, and chemokines involved in migration, proliferation, and 
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activation of fibroblasts [197]. Additionally, the donor for these NHLF cells does not fit 
the typical profile for healthy lung tissue. This particular donor was a 79 year old female 
with a history of smoking. Age related cellular senescence and tobacco use have both been 
associated with increased levels of PAI-1, so the fibrinolytic system in these “normal” 
fibroblasts may be dysregulated compared to a younger non-smoking donor [198]. 
Stimulation with hydrogen peroxide alone demonstrated highly significant 
decreases in the rates of fibrinolysis (P < 0.1) suggesting a critical role of ROS in the 
process of cell-mediated fibrinolysis. In contrast, conditions that included TGF-β1 showed 
no significant difference upon further stimulation with exogenous hydrogen peroxide. This 
non-additive effect is consistent with a notion that the effects of adding exogenous H2O2 
and exogenous TGF-β1 converge [199]. That is, TGF-β1-triggered increase in endogenous 
H2O2 production [200, 201], may mask effects of any exogenous H2O2 addition. Such 
effects may also work in concert with ROS-induced reduction in TGF-β1 receptors [43].  
The two FDA-approved IPF drugs, nintedanib and pirfenidone, did not show a 
significant impact on fibrinolysis. These therapeutics have established anti-fibrotic effects, 
so these results indicate that the mechanism of action for nintedanib and pirfenidone may 
not be related to fibrinolytic activity of lung fibroblasts. As the precise mechanisms of 
action of these FDA-approved drugs are not known, the “negative” results of these drugs 
on fibroblast-mediated fibrinolysis is in and of itself of intellectual value. The experimental 
drug diethyl-pythiDC, on the other hand, significantly (P < 0.05) delayed fibrinolysis. 
Diethyl-pythiDC is a selective inhibitor of prolyl 4-hydroxylase, an enzyme best known 
for structure-stabilizing modifications of collagen [196] that also acts on a variety of 
proteins [202] including hypoxia inducible factor 1 [199, 203]. The ability of diethyl-
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PythiDC to reduce fibroblast-mediated fibrinolysis is also a novel finding and demonstrates 
the utility of our assay. 
While our assay is effective for finding molecules that modulate cell-mediated 
fibrinolysis, the lack of a significant effect with established IPF therapeutics does reveal 
limitations of using this assay for testing anti-fibrotic drugs. Although fibrinolytic 
proteases are known to play a significant role in IPF progression, their effects can be 
through non-fibrinolytic effects that our assay would miss, such as activation of protease 
activated receptors (PARs) [204]. Nintedanib and pirfenidone are also reported to exert 
anti-fibrotic effects through direct binding to collagen fibrils to inhibit their assembly 
[205], another mechanism of action our assay would miss. 
3.4 Conclusions 
This work describes an approach for ATPS-based printing of microscale cell-laden 
fibrin scaffolds. A droplet comprised of the heavier phase partitions cells and fibrinogen 
while the bulk phase provides thrombin to promote localized enzymatic crosslinking, 
leading to controlled production of microliter-scale fibrin constructs. Automated label-free 
image processing quantified rates of cell-mediated fibrin degradation from time-course 
brightfield images. We found that primary human lung fibroblasts degrade the fibrin 
scaffold at a rate dependent on source of cells, cell density, and the presence of soluble 
factors. Given the variety of contributors to dysregulation of fibrinolysis seen in cancer, 
fibrosis, and metabolic disease; this phenotypic assay for cell-mediated fibrin degradation 
provides a potentially valuable research tool for further studies in these and other fields. 
Additionally, the technique developed here for aqueous two-phase printing of cell-laden 
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CHAPTER 4. LUNG SCARRING-IN-A-WELL‡  
 Tissue damage often triggers rapid clotting followed by a slower, cell-mediated 
repair process of clot dissolution, deposition of new extracellular matrix, and contracture. 
This paper recreates key steps in this tissue repair process in 96-well plates using primary 
human lung fibroblasts and microscale fibrin clots. These cell-laden gels are formed by 
aqueous two-phase micro-printing, and the cell-mediated matrix remodeling is monitored 
by time-lapse microscopy and automated image processing. Stimulation of this wound 
healing model with the pro-fibrotic cytokine TGF-β1 leads to an excessive scar formation 
response that manifests as a combination of slowed fibrinolysis and increased collagen 
production. Addition of drugs also shifted the scarring profile: the two FDA-approved 
fibrosis drugs (nintedanib and pirfenidone) and a collagen cross-linking inhibitor Diethyl-
pythiDC reduced collagen deposition while a PAI-1 inhibitor, TM5275, and an autotaxin 
inhibitor, GLPG1690, reduced both collagen production and fibrinolysis time. An NMDA 
inhibitor, NP-120 also known as Ifenprodil, slightly increased collagen levels while a 
protease inhibitor, aprotinin, drastically delayed fibrinolysis and also increased collagen 
deposition. Not only is the assay useful for functional differentiation of drug action, it is 
highly sensitive; one of the few in vitro assays that can clearly detect Pirfenidone effects 
at physiological concentrations. Although this paper focuses on lung fibrosis, the approach 
opens new opportunities for studying a broad range of fibrotic diseases and for evaluating 
anti-fibrotic therapeutics. 
                                                 
‡ At the time of dissertation submission, this chapter was under preparation for submission 
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4.1 Introduction 
Fibrin degradation and collagen deposition are central to the wound healing process 
[206, 207]. The provisional fibrin matrix is formed by coagulation following initial injury 
and provides a temporary scaffold for tissue repair. Because fibrin lacks the organization 
of native interstitial extracellular matrix (ECM) it is gradually replaced through processes 
including cell-mediated fibrin degradation and collagen deposition [170, 208]. 
Dysregulation of this matrix turnover can result in pathological conditions such as 
fibroproliferative disease from chronic excessive collagen deposition [8, 209]. This 
dysregulation can result from multiple contributing pathways; however, there are currently 
no in vitro assays to evaluate multifactorial contributions to fibrin remodeling. Due to the 
variety of cytokines, proteases, inhibitors, and biomechanical factors that combinatorially 
influence remodeling [125, 175, 178, 210], a high-throughput phenotypic assay would be 
well suited to evaluate cell-mediated fibrin remodeling for applications in wound healing 
and fibrosis. 
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disorder of aberrant 
ECM accumulation in the lungs. Current FDA-approved drugs for IPF can only slow, not 
halt or reverse, disease progression [211-213]; but several recent reviews have proposed 
regulators of fibrinolysis as potential targets for future IPF treatment strategies [214-216]. 
Evidence indicates that IPF progression is driven in part by a hypercoagulable and anti-
fibrinolytic environment, where fibrin forms in the absence of exogenous tissue damage 
and degrades more slowly than the healthy physiological rate [26, 217]. However, specific 
mechanisms linking fibrin persistence to tissue fibrosis remain unclear. Different theories 
suggest that downstream signaling of the fibrinolytic system, mechanical persistence of the 
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fibrin scaffold, or biophysical feedback between cells and ECM may contribute to this 
pathological fibrin remodeling in fibroblasts [178, 179, 218-220].  
Our lab recently established a technique to print unprecedentedly small cell-laden 
fibrin matrices by implementing aqueous two-phase systems (ATPS). ATPS printing 
enabled separation of fibrinogen and thrombin in two distinct immiscible aqueous phases 
so that thrombin must diffuse between phases before crosslinking. This method for ATPS 
fibrin micro-printing was previously implemented to establish an assay for cell-mediated 
fibrinolysis. The conditions in this prior study, however, did not provide readouts of 
fibrotic processes such as collagen deposition, which typically accompanies fibrinolysis in 
wound healing and scarring.  
In this work, we adapt our prior ATPS fibrin micro-printing technique to enable high-
throughput label-free analysis of scarring. This adaptation built upon our finding that a 
more physiological higher seeding density, and use of serum, promoted fibroblast 
differentiation and collagen deposition in addition to fibrin degradation. The fibrin 
microgels were then stimulated with pro-fibrotic cytokines to evaluate mRNA expression 
and ECM deposition. Multiple donors for normal and diseased lung fibroblasts were 
utilized in order to evaluate consistency in response to therapeutic stimuli and investigate 
the interplay between fibrinolysis and collagen deposition at physiologically relevant 
concentrations of these compounds. To our knowledge, this is the first in vitro assay to 
conveniently combine label-free readouts for fibrin degradation, collagen synthesis, and 
cell contraction to evaluate fibrotic tissue remodeling. 
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4.2 Materials and Methods: 
4.2.1 Cell culture and ATPS reagents 
A stock solution of DEX (20% w/w dextran T500; Sigma) was prepared in PBS on 
a rocker overnight. A stock solution of PEG (6% w/w, 35k MW; Sigma) was prepared in 
fully supplemented culture media with 10% deionized water to balance osmolality. Both 
stock solutions were passed through a 0.22 μm sterilizing syringe filter before storage. PEG 
working solutions were stored for up to 2 weeks at 4C. Thrombin (Human Alpha 
Thrombin; Enzyme Research Labs) was also added to the PEG solution at a concentration 
of 0.1 U/mL immediately preceding experiments. Fibrinogen-DEX solutions were 
prepared by diluting fibrinogen stock solution (human fibrinogen 3; Enzyme Research 
Labs) to a final concentration of 4 mg/mL in a sterile solution of 4% 10x DMEM, 15% 
DEX stock solution (to a final concentration of 3% dextran), and 50% cell suspension in 
growth media. For all experiments, the cell suspension was diluted for 2500 cells per 
microliter in the final fibrinogen-DEX solution. 
4.2.2 Cell preparation 
Human primary lung fibroblasts were used in all experiments presented in this 
chapter. Unless otherwise noted, experiments utilized normal human lung fibroblasts 
(NHLF B lot#0000580583; Lonza) from a 79 year old female with a history of smoking. 
For experiments evaluating donor variability, the following cells were utilized: NHLF A 
(NHLF lot#0000608197; Lonza) from a 67 year old male, IPF A (IPF lot#0000627840; 
Lonza) from a 52 year old male, and IPF B (IPF lot#6F5002; Lonza) from a 83 year old 
male. All cells were cultured in fibroblast growth media (FGM; Lonza). Cells were 
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passaged at 80-90% confuence, and were sub-cultured in 1:3 ratios by trypsinization. When 
at the desired confluence, cells were washed with PBS and 0.05% trypsin solution was 
added to the flask. Cells were incubated for 2 min, and then harvested and centrifuged (200 
xg, 5min) in a conical tube. The supernatant was aspirated and the cell pellet was re-
suspended in serum-free culture media. When used in fibrin degradation experiments, cells 
were re-suspended at 2x the final desired concentration (2500 cells/μl unless otherwise 
indicated). All experiments were conducted with cells at or below passage 8 except for 
high passage experiments conducted at passage 12. In all experiments, media was changed 
every 48 hours and any media additives (plasminogen, TGF-β1, drugs, etc) were included. 
4.2.3 ATPS printing of fibrin microgels 
ATPS printing of fibrin micro-scaffolds was previously documented in Chapter 2. 
Briefly, working solutions of PEG with 0.1 U/mL of thrombin were warmed to 37C and 
pipetted into a 96-well plate. For production of droplets, fibrinogen-DEX solutions with 
cell suspension were maintained at 37C and 4 μl per assay (unless otherwise noted) was 
pipetted directly into the PEG-thrombin media using a semi-automated repeater pipette 
(Repeater E3X; Eppendorf). Following dispensing of the DEX phase, the plates were 
placed in an ambient air incubator at 37C for 30 min to allow the thrombin to enzymatically 
crosslink the fibrinogen into a fibrin matrix (Figure 15A). The PEG-enriched media was 
removed using a 12-channel micropipette and replaced with 100 μl of fully supplemented 
media in each well. When applicable, this media addition was supplemented with stimuli 
as detailed in section 2.7. For the duration of each experiment, assay plates were imaged 
every 2 hours at 4x with an automated cell culture monitoring system (Incucyte S3; Essen 
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Biosystems). As the assay proceeded, the fibroblasts progressively remodelled the fibrin 
scaffold as illustrated in Figure 15C.  
4.2.4 Histologic analysis of fibrin microgels 
Contracted assays were harvested after 12 days of culture. These assays were 
prepared for histology, stained, and imaged as previously described for cultured spheroids. 
Briefly, the assays were washed with PBS and fixed in 4% paraformaldehyde (Alfa Aesar) 
for 1 hour at room temperature. The assays were stained with 0.5% methylene blue solution 
in PBS for 10 minutes at room temperature to aid in visualization during histology. Samples 
were placed in a cryomold containing optimal cutting temperate (OCT), and flash frozen 
in cooled isopentane. 10 um sections were obtained using a CryoStar NX70 cryostat 
(Thermo Fisher Scientific).   
Upon warming to room temperature, the sections were washed with PBS, 
permeabilized with 0.2% Triton-X 100, and blocked for 1 hour at room temperature with 
4% bovine serum albumin (BSA) (Millipore Sigma). Sections were stained for 30 min at 
room temperature with Sirius red (0.1% of Sirius red in saturated aqueous picric acid), as 
previously described for collagen bundle staining [221]. The samples were then washed 
with PBS, stained with DAPI for 15 minutes at room temperature, and coverslipped. 
Samples were imaged using a DMi8 microscope (Leica) equipped with 10x and 20x air 
objectives. Fluorescence was detected using Texas Red channel settings as previously 
described [222]. Mean fluorescence intensity was quantified in ImageJ as the average pixel 
intensity within the sectioned assay. 
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4.2.5 mRNA quantification by qPCR 
RNA extraction and qPCR: 12 fibrin assays at the indicated time points were pooled 
together per condition, and lysed with 350 μl of RLT lysis buffer. RNA was extracted from 
assays using an RNeasy Mini Kit (Qiagen, #74104) and was performed according to the 
manufacturer’s instructions. RNA sample concentration was measured using a NanoDrop 
OneC Spectrophotometer (Thermo Fisher Scientific). A High-Capacity RNA-to-cDNA Kit 
(Applied Biosystems, #4387406) was used for reverse transcription; 400 ng of RNA for 
each sample was mixed with 10 μl primer, 1 μl reverse transcriptase enzyme and nuclease-
free water to bring the final reaction volume to 20 μl. The reaction was performed for 60 
minutes at 37 C, followed by 5 minutes at 95 C using a Veriti Thermal Cycler (Applied 
Biosystems). qPCR was performed using a QuantStudio 3 Real-Time PCR System 
(Applied Biosystems). Each reaction consisted of 1 μl cDNA, 10 μl TaqMan Fast advanced 
master mix (Applied Biosystems, #4444556), 1 μl primer, and 6 μl nuclease-free water. 
TaqMan primers (Applied Biosystems) for smooth muscle actin (ACTA2, 
Hs00426835_g1), plasminogen activator (PLAT, Hs00263492_m1), Plasminogen activator 
inhibitor-1 (SERPINE1, Hs00167155_m1), collagen type I (COL1A1, Hs00164004_m1), 
plasminogen activator (PLAU, Hs01547054_m1), and Ki67 (MKI67, Hs01032443_m1) 
were utilized. The QuantStudio 3 was programmed with a 2 minute hold at 95 C, followed 
by 40 cycles of 95 C for 1 second and 60 C for 20 seconds. Each sample was run with 
biological triplicates. The relative gene expression was calculated using the 2-ΔΔCT 
method, with glyceraldehyde-3-phosphate dehydrogenase as the housekeeping gene 
(GAPDH, Hs02786624_g1). Fold changes were normalized with respect to the time zero 
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timepoint with no TGF-β1 stimulation, and are reported as the mean with the error bars 
representing the minimum and maximum values. 
4.2.6 High-throughput brightfield image analysis 
After each experiment, brightfield images at two hour intervals from the 4x 
objective of our automated cell culture monitoring system (Incucyte S3; Essen Biosystems) 
were downloaded in jpeg format from the automated cell culture monitoring system. 
Separate processes for pixel classification, thresholding, and morphological filtering were 
implemented for the masking approach illustrated in Figure 17A in order to isolate the 
assay area from the background.  
Image segmentation implemented Ilastic, a freely available image classification 
tool developed by the European Molecular Biology Laboratory. Ilastik’s pixel 
classification utility implements a random forest classifier for quick and robust 
segmentation. In order to train the classifier, 10 characteristic images were selected to 
include different stages of ECM remodeling. In this step, each individual pixel is assigned 
a probability for belonging to layers for the background or the assay. Ilastik enables 
interactive training of the random forest classifier via user annotations of the training 
images. All default features (σ = 0.3 through 10 for intensity, edge, and texture) were 
utilized for this interactive training by methodically annotating mislabelled areas of each 
training image. Care was taken to equally annotate background and assay areas in order to 
prevent the algorithm from weighting features inappropriately. Through this iterative 
training method, the user can evaluate interactive predictions by the algorithm and then 
draw additional annotations to correct mistakes. When additional training annotations no 
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longer improved background noise and edge feature fit of the predicted mask over the assay 
area, the trained classifier was saved for future use. With each experiment, this trained 
classifier was reloaded and assay fit was evaluated on representative images (not from the 
training set) before use. 
This pixel classification workflow performs semantic segmentation, and therefore 
returns a probability map for the background and assay area for each image. The probability 
map was transformed into background as assay area objects through thresholding. 
Thresholding of these probability masks then enabled generation of a single mask to isolate 
the assay area. A closing morphological filter with a 25x25 kernel was then applied to each 
mask in order to remove noise. This masking approach was implemented for each time-
course brightfield image for every condition over the course of an experiment. 
The area from segmented masks was used to quantify assay contraction. For each 
experimental replicate, a sigmoid curve was fit using the curve_fit function from the SciPy 
library in Python. The logistic function given by the equation in Figure 17C enabled 
automated extraction of the time point for 50% contraction and the maximum slope at the 
equation’s centroid. In many cases, the final contracted assay was out of view for the 4x 
objective in the live cell imager. For this reason, final assay area was determined from 
brightfield images taken on a benchtop imaging system (2x objective; EVOS M7000; 
ThermoFisher) and evaluated by the same segmentation procedure described above. 
Various concentrations of transforming growth factor type β1 (Human 
Recombinant TGF-β1; Peprotech) were used for validation due to its established anti-
fibrinolytic and pro-fibrotic qualities. TGF-β1 was added at indicated concentrations in the 
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assay media which was used to rinse and remove ATPS polymers after incubation. In order 
to visualize dynamics between assay contraction time and final assay area, kernel density 
estimate plots (KDE plots) were generated using the Seaborn Statistical Data Visualization 
library in Python 3. These bivariate kernel density estimates represent the probability 
density functions for each experimental condition. 
In order to evaluate metrics not based on changes in assay area, the segmented 
images were used to generate masks that isolate the assay from image background. Within 
these masked regions, a variety of metrics were evaluated including average intensity, 
standard deviation, kurtosis, and skew from histograms of pixel intensity. Plots of time 
course changes in average pixel intensity were generated to evaluate ECM composition. 
4.2.7 Phenotypic evaluation of stimuli 
Our customized high-throughput image analysis approach was applied for 
phenotypic evaluation of all experiments. In order to evaluate assay remodeling behavior 
with established stimuli; experiments implemented different conditions of TGF-β1, serum, 
and cell seeding density. TGF-β1 was introduced at concentrations of 0, 0.5, 2, and 10 
ng/mL; however the highest concentration did not contract within the duration of the 
experiment and was therefore omitted from analysis. In order to evaluate the remodeling 
effects of serum, foetal bovine serum (FBS, Lonza) at concentrations of 0, 1, 2, 4, and 8% 
by volume of the cell culture media was added during the washing step after fibrin 
crosslinking. For cell seeding density experiments, fibroblasts were suspended at 
appropriately modified concentrations in the dextran phase of the ATPS fibrin printing 
 78 
formulation so that assays were printed with concentrations of  1, 2, 4, and 8 thousand cells 
per microliter within a 4 μl assay. 
In order to evaluate the capability of this assay to test the fibrinolytic and anti-
fibrotic effects of therapeutic stimuli, a variety of drug compounds were introduced to the 
assays after the wash step. This included 1.0 μM  ifenprodil (MedChemExpress), 1 μM 
nintedanib (Selleck Chem), 500 μM pirfenidone (Selleck Chem), 10 μM TM5275 
(MedChemExpress), 0.50 μM aprotinin (MedChemExpress), 1.0 μM  GLPG 1690 
(MedChemExpress), and 20 μM diethyl-pythiDC (AOBIOUS); all diluted and stored 
according to supplier data sheet recommendations. These concentrations were established 
in preliminary experiments that evaluated a range of concentrations used in prior literature. 
These stimuli were freshly mixed for each media change during experiments, and a 
minimum of four replicates were tested per experimental condition. 
4.2.8 Statistical Analysis 
All experimental values are reported as means ± standard deviation. ANOVA tests 
were performed using the statsmodels library in Python 3 with the Tukey test for post-hoc 
pairwise comparisons. Experiments involving two independent variables (such as 
therapeutic stimulus and TGF-β1) implemented two-way ANOVA to evaluate the 
significance of combined effects. Kernel density estimates were determined for KDE plots 




4.3 Results and Discussion 
In tissue repair, fibrin formation is followed by fibroblast migration, fibrinolysis and 
matrix remodeling. We previously reported a method to print microscale cell-laden fibrin 
gels to quantify cell-mediated fibrinolysis. Our prior study conditions, however, did not 
provide readouts of fibrosis formation such as collagen deposition and fibroblast activation.  
 In the work described here, we adapt our prior ATPS fibrin micro-printing 
technique to allow for high-throughput automated image-based analysis of 
fibroproliferation as well as fibrinolysis. This adaptation built upon the finding that a higher 
seeding density and the use of serum-supplemented media enabled fibroblast proliferation, 
differentiation, and collagen deposition. This newly discovered model for fibrin 
remodeling was characterized by staining histologic slices of remodeled matrices and 
quantifying mRNA expression in order to elucidate which proteins were affecting matrix 
turnover. Then, an automated image processing approach quantified different aspects of 
matrix remodeling from label-free brightfield images. Finally, the microscale cell mediated 
fibrinolysis-fibrosis assay was implemented to evaluate the effects of anti-fibrotic 
therapeutics on fibroblasts from normal and diseased donors. 
4.3.1 Fabrication of microscale fibrin matrices 
Biological environments establish fibrin matrices through coagulation, where a 
cascade of clotting factors activates thrombin to enzymatically crosslink fibrinogen into 
fibrin [161]. Similarly, synthetic fibrin scaffolds are formed by exposing monomeric 
fibrinogen to activated thrombin [181]. Our previously established technique for 
generating fibrin micro-scaffolds utilized an ATPS with PEG and dextran to improve  
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Figure 15. ATPS fibrin printing and cell-mediated remodeling: (a) Process schematic of 
ATPS generation of microscale fibrin droplets and subsequent remodeling. After the initial pipetting 
step, thrombin from the PEG phase diffuses into the dextran phase for controlled crosslinking of 
fibrinogen into fibrin over the incubation period. Subsequent remodeling includes concurrent 
fibrinolysis and collagen deposition, followed by contraction. (b) Characteristic brightfield microscope 
images (taken at 4x magnification) illustrate the assay progression when stimulated with 2 ng/mL of 
TGF-β1. Scale bars are 1 mm. (c) Microscale illustration shows the changes in ECM organization at 
stages of remodeling. Fibrosis denotes deposition and accumulation of fibrous extracellular protein. 
control over enzymatic crosslinking, which enables printing of unprecedentedly small cell-
laden fibrin matrices with standard liquid handling equipment. This prior implementation 
of fibrin micro-printing was used to evaluate fibroblast-mediated fibrinolysis by utilizing 
lower seeding density (1000 cells/μl) in combination with a concentration of exogenous 
plasminogen comparable to levels found in serum [223]. However, most tissue in vivo is 
not exposed to serum-level concentrations. The majority of plasminogen is produced in the 
liver, so tissue availability depends on vascular permeability to plasma proteins [224]. In 
the current work, decreased availability of plasminogen in addition to higher fibroblast 
seeding density and serum supplemented media result in a significantly altered trajectory 
of fibrin remodeling compared to our prior approach. Rather than strictly degrading the 
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scaffold into fibrin degradation products and dissociated cells, these conditions enable 
deposition of significant collagen and contraction into a fibrotic spheroid.  
In this approach, a microscale format was necessary to enable microplate 
implementation and evaluation with a conventional live-cell imager. In order to fit the 
entire assay within the field of view of a 4x objective, the fibrin scaffold needed an initial 
volume below 8 μl. In order to establish this microscale fibrin environment, we 
implemented ATPS printing as previously described. The necessity for this ATPS 
environment in our microscale fibrin degradation assay comes from the capability of 
aqueous two-phase partitioning to control diffusion of thrombin into the fibrinogen droplet. 
This restricts enzymatic crosslinking of cell-laden fibrin matrices until after the droplets 
have been dispensed (Figure 15A). After a 30 minute incubation period, the fibrin was 
sufficiently polymerized and the ATPS solutions could be rinsed and replaced with growth 
media and stimulants for specific conditions.  
During assay progression, remodeling is visually apparent in brightfield images as 
opaque fibrin transitioning into a translucent fibrous matrix and eventually contracting into 
a dense spheroid (Figure 15 B, C).  Our previously implemented fibrin degradation assay 
demonstrated the opaque material to be fibrin, so qualitative analysis of the current assay 
indicates concurrent fibrinolysis and deposition of cell-secreted ECM. In the absence of 
serum, which contains plasminogen, the initial fibrin matrix remained opaque and intact 
with minimal change (Supplemental Video 2). Control conditions verified that presence of 
both serum and cells was necessary for degradation of the opaque fibrin scaffold, indicating 
that cell mediated activation of plasmin was necessary for fibrin degradation. Factors 
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contributing to altered fibrinolysis and increased collagen deposition are assessed in the 
following section. 
4.3.2 Response to TGF-β1 
Exogenous addition of TGF-β1 served as a broad pro-fibrotic stimulus to determine 
whether varying degrees of fibrosis are distinguishable in the context of this assay. 
Downstream signaling effects include inhibition of fibrinolysis, increased fibroblast 
proliferation, increased synthesis and deposition of connective tissue, and inhibition of 
connective tissue breakdown [225]. Preliminary qualitative assessment of microscale fibrin 
remodeling in our assay indicated dose-dependent increases in both timing of contraction 
and final contracted assay size. Specific biological contributions to these differences in 
remodeling were evaluated through histologic staining and qPCR analysis. 
4.3.2.1 Final organization of deposited collagen 
Histologic evaluation was used to determine the ECM content and organization of 
collagen in the final contracted assays. The most commonly used commercially-available 
method for quantification of deposited collagen is the Sircol™ insoluble collagen assay 
kit, which implements the dye Sirius Red F3B due to its high specificity for collagen [226]. 
These kits, however, are optimized for use on fixed quantities of excised tissue. Due to the 
low assay volume and variability in assay final size (Figure 16A), Sircol™ kits were not 
practical for use in this approach. Many alternative methods for benchtop quantification of 
collagen rely on ELISAs to evaluate soluble collagen and products of collagen synthesis. 
These methods were also infeasible for our application due to high background protein 
concentrations from the serum-supplemented media. 
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Figure 16. Matrix remodeling in vitro: (a) Brightfield images of histologic sections show the 
difference in final size between assays treated with varied concentrations of TGF-β1. The contracted 
assays were harvested after 12 days, and sections were stained with picrosirius red. Scale bars are 
250μm. (b) Evaluation of mean fluorescence intensity demonstrates consistency in collagen 
organization between conditions. Quantification of mRNA expression via qPCR evaluated dose-
dependent time-course changes in SERPENE1 (c), COL1A1 (d), ACTA2 (e), PLAU (f), PLAT (g), 
MKI67 (h) in response to concentrations of TGF-β1. The dotted lines indicate the zero time point used 
as reference for relative expression. Two-way ANOVA indicated significant combined effects of time 
and TGF-β1 for COL1A1 with P < 0.01; significant one-way effects for both variables with 
SERPENE1, PLAU, PLAT, and ACTA2 with P < 0.01; and significant one-way effects for only TGF-
β1 concentration for MKI67 of P < 0.01. 
Picrosirius red (PSR) utilizes the same anionic dye as Sircol™ assay kits to 
visualize collagen in paraffin embedded tissue sections. Under light microscopy, PSR 
stained collagen appears red and can be used for qualitative evaluation of collagen 
organization [221]. A variety of quantitative approaches for morphometric assessment of 
collagen networks implement polarized light to visualize fiber alignment; however, signal 
strength and hue under linear polarized light are heavily dependent on sample orientation 
[227]. Fluorescent imaging of PSR stained tissues with standard red filter sets yields a 
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strong red fluorescence signal that is sensitive, collagen-specific, and is unaffected by 
sample orientation [222, 227]. 
In order to evaluate deposited collagen, contracted assays were collected after 12 
days of culture. Intermediate time points could not be sectioned due to adhesion of flat 
fibrin scaffolds to the microplate. Stained sections demonstrated consistent appearance of 
collagen between conditions, with a consistent increase in size for higher concentrations of 
TGF-β1 (Figure 16A). Fluorescent micrographs demonstrate relatively homogenous 
collagen distribution for the interior of the contracted assay with higher deposition at the 
interface between the assay and the media. Evaluation of area demonstrated a dose-
dependent increase in final contracted assay size (P < 0.05).  Mean fluorescence intensity 
(MFI) was measured in order to evaluate relative differences in collagen organization 
between sections (Figure 16B). While this measure cannot provide absolute quantification 
of collagen content, it indicated relative consistency in organization of collagen networks 
between different TGF-β1 conditions and the control. 
Well-established mechanisms have linked TGF-β1 signaling to exaggerated 
extracellular deposition of type I collagen in fibrosis [228]. Here, histologic evaluation 
demonstrated consistency in organization of collagen between histologic slides. This 
indicates that assay size is at least partially influenced by the total amount of collagen 
accumulated during assay progression; however, there are likely differences in collagen 
compaction due to variations in fibroblast contractility between conditions. Additional 
analysis is necessary to better characterize variability in collagen density. Potential 
contributors to collagen remodeling are evaluated in the following section. 
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4.3.2.2 Alterations in mRNA expression 
In order to further evaluate the factors contributing to altered ECM remodeling with 
TGF-β1 stimulation, qPCR was used to determine mRNA expression for proteins involved 
in fibrinolysis and collagen deposition. These genes were chosen for their involvement in 
specific pathways contributing to slowed fibrinolysis, increased collagen deposition, and 
increased myofibroblast activation in response to TGF-β1 stimulation. Time points at 12, 
24, and 36 hours evaluated time-dependent and dose-dependent response to TGF-β1 within 
the dynamic fibrin-remodeling environment. Quantification of mRNA for SERPENE1 
demonstrated significant time-dependent and dose-dependent increases in expression in 
response to TGF-β1 (Figure 16C).  
The induction of SERPENE1 by TGF-β1 signaling is a well-established connection 
between TGF-β1 and fibrinolysis because SERPENE1 encodes the protein plasminogen 
activator inhibitor type 1 (PAI-1) [229]. PAI-1 is the dominant inhibitor of fibrinolysis, and 
acts by binding to the active sites of urokinase-type and tissue-type plasminogen activators 
(uPA and tPA). These three regulators have been evaluated extensively in animal models 
of IPF to evaluate their potential involvement in fibrosis pathogenesis [177]. TGF-β1 
mediated increases in PAI-1 contribute to the anti-fibrinolytic environment during certain 
stages of wound healing and fibrosis [230]. Additionally, gene polymorphisms of TGF-β1 
and PAI-1 have been associated with susceptibility to IPF due in part to dysregulation of 
the fibrinolytic system [231]. 
Time course measurements also show significant increases in expression of the 
genes for tPA and uPA relative to the initial time point, but the effect of TGF-β1 stimulation 
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is inverted between these two plasminogen activators. uPA demonstrated relative 
upregulation compared to the control time series, while tPA demonstrated a relative 
downregulation (Figure 16 D, E). However, the qPCR results for tPA and uPA do not 
indicate relative quantities between the two, so additional quantitative evaluation is 
necessary to determine the dominant TGF-β1 mediated changes.  
This highlights the potential utility for a phenotypic assay in evaluating 
multifactorial contributions to fibrotic remodeling. While PAI-1 is generally credited as 
the anti-fibrinolytic mediator in fibrosis, other components of the fibrinolytic system 
demonstrate significant differential expression in response to a pro-fibrotic stimulus. 
Additionally, there are several other activators and inhibitors not evaluated here that are 
produced by cells and play roles in regulating conversion of plasminogen into plasmin 
[170-174]. This phenotypic evaluation of fibrin remodeling can incorporate these effects 
even though expression of individual contributing proteins was not specifically quantified. 
In addition to its effects on the fibrinolytic system, TGF-β1 also has established 
roles in myofibroblast activation and collagen synthesis [192]. Myofibroblasts are 
collagen-producing cells that express the contractile protein alpha smooth muscle actin 
(αSMA). Increases in myofibroblast activation and myofibroblast resistance to apoptosis 
have been identified as major contributors to IPF pathogenesis [12]. Evaluation of ACTA2 
mRNA demonstrated significant time-course increases in αSMA expression as well as 
increased expression for the highest concentration of TGF-β1 (Figure 16F). These time-
course changes may be due to a variety of factors including biomechanical feedback, 
cytokine secretion, or downstream signaling of the fibrinolytic system [12, 232, 233]. 
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COL1A1 encodes the pro-alpha1(I) chain, which is a primary component of type I 
collagen. Quantification of mRNA for COL1A1 demonstrated significant combined effects 
of TGF-β1 and time (Figure 16G). Collagen expression in pulmonary fibrosis is heavily 
dependent on myofibroblast activation [234], but increased collagen expression in 
fibroblasts has also been linked to downstream effects of anti-fibrinolytic environments 
[220]. Due to the variety of TGF-β1 effects on cellular activity, the increased expression 
of COL1A1 likely results from the combinatorial effects of multiple contributing pathways. 
Expression of MKI67 mRNA was evaluated as a marker for proliferation. The 
substantial decrease from initial RQ reference value to the first time point may be due to 
that time point’s proximity to trypsinization and manipulation during experimental setup 
(Figure 16H). In later time points, MKI67 expression was significantly upregulated with 
higher concentrations of TGF-β1, indicating increased cellular proliferation relative to the 
control condition. TGF-β1 is a key regulator of ECM remodeling and dysregulation of 
TGF-β function is closely associated with fibrosis [228]. Our assay reveals multiple effects 
of TGF-β1 on fibroblasts including its ability to impact ECM remodeling through 
regulation of the fibrinolytic system and upregulated collagen synthesis. 
4.3.3 Label-free quantification of fibrotic remodeling 
In order to evaluate fibrosis in vitro, conventional approaches generally quantify 
specific contributors such as activation of myofibroblasts or concentration of soluble 
collagen. Here, an automated approach was developed in order to broadly assess 
phenotypic changes associated with fibrin remodeling. Preliminary qualitative assessment 
indicated that pro-fibrotic stimulation with TGF-β1 increased the time before assay  
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Figure 17. High-throughput quantification of fibrin Remodeling: (a) The segmentation 
approach utilized Ilastik for pixel classification and the Python OpenCV library for thresholding and 
morphological filtering. Example images from diverse stages of assay remodeling were chosen to 
demonstrate the resilience of this segmentation approach to different image features. (b) The resulting 
masks enabled calculation of assay area, as illustrated here with NHLF cells and different 
concentrations of TGF-β1. (c) An example measurement demonstrates image metric extraction for 
NHLF cells with no TGF-β1. For each individual microwell, the logistic function is fit using a least 
squares regression. This function enabled extraction of 50% contraction time (d), maximum 
contraction rate (e), and final area (f). Note that the 50% contraction time (vertical axis) is indicated 
here as days after start of assay, contraction rate in mm2 per day, and final area in mm2. (Statistical 
significance:  ab, bc = P < 0.01;  bd = P < 0.05) 
contraction and increased the final assay size after contraction. There were also changes in 
assay appearance associated with the transition from an opaque fibrin matrix to a 
translucent collagen matrix. 
The first step of image analysis was to isolate the assay from the background of 
each image. Due to transitions in assay appearance during remodeling, the basic image 
segmentation software for our live-cell imager was inadequate for accurate segmentation. 
In order to consistently isolate assay area, it was necessary to implement an approach that 
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utilized machine learning. Our approach utilized Ilastic, a freely available image 
classification tool developed by the European Molecular Biology Laboratory. 
Ilastik’s pixel classification tool utilizes a random forest algorithm that can be 
interactively trained through iterations of user annotations on a small set of training images. 
It was important here to use training images from time points throughout the experiment 
with a variety of different image features. Otherwise, the trained algorithm might mis-
classify brightfield images from stages of remodeling that were omitted from the training 
set. When additional training annotations no longer improved background noise and edge 
feature fit, the trained pixel classification algorithm was saved for future use. Figure 17A 
illustrates the output of this pixel classification algorithm. Ilastik performs semantic 
segmentation, which returns probability maps that can be converted into masks by 
thresholding. In order to remove remaining background noise, opening and closing 
morphological filters were applied to the masks. 
After establishing segmented masks, time-course changes in assay area were 
plotted in order to visualize assay remodeling (Figure 17B). Fitting time-course data from 
each individual well with a sigmoidal curve facilitated extraction of the time point for 50% 
contraction and the maximum slope at the sigmoid’s centroid (Figure 17C). Figure 17D 
shows changes in the 50% contraction time point in response to different TGF-β1 
concentrations. ANOVA indicated statistical significance of these differences in 
degradation time (P < 0.01), and post-hoc pairwise analysis with the Tukey test 
demonstrated statistically significant differences between specific conditions. The dose-
dependent increases in time for 50% contraction correspond with changes in mRNA 
expression from the previous section.  
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Maximum contraction rate (Figure 17E) was determined as the centroid slope of 
the sigmoidal fit for each experimental replicate (Figure 17C). This value reflects 
contractile stress generated by cells within the assay. In order for contraction to initiate, 
stress within the assay must overcome adhesion to the microwell. In some cases, initial 
contraction was not sustained and occurred in multiple steps (Appendix Figure A-5). Due 
to this inconsistency, the slope of contraction did not serve as a reliable indicator of assay 
remodeling activity. 
Final contracted cross-sectional area was also evaluated in our analysis, and 
demonstrated significant dose-dependent increase with TGF-β1 stimulation (Figure 17F). 
COL1A1 mRNA quantification and histologic analysis demonstrated increased collagen 
synthesis and deposition in response to TGF-β1. Additionally, qualitative evaluation of 
assay appearance and pixel intensity quantification leading up to contraction (Appendix 
Figure A-4) also indicate increased deposition of collagen with TGF-β1. These data and 
observations together suggest that final contracted cross-sectional area of the assay is 
correlated with total collagen deposition. However, variability in collagen density due to 
differences in generation of contractile stress likely also contribute to final cross-sectional 
area due to differences in compaction density. Fibroblast proliferation may also play a role. 
Additional evaluation is necessary to determine relative contributions to final cross-
sectional area.  
PAI-1 may be particularly relevant in this remodeling process due to its multiple 
effects on fibrin remodeling. In addition to inhibiting fibrinolysis, PAI-1 can disrupt 
integrins, which form cell-matrix adhesions [218]. Appendix Figure A-4 shows increasing 
pixel intensity leading up to assay contraction. We previously established that this increase  
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Figure 18. TGF-β1, serum concentration, and seeding density effects: Output contraction 
times and final assay areas from image processing analysis were used to plot kernel density estimates 
showing interplay between contraction time and final assay area. (a) Stimulation with TGF-β1 resulted 
in increases in both 50% contraction time and final assay area. (b) Evaluation of serum concentration 
demonstrated relatively consistent contraction time with increasing final assay area in response to 
higher serum concentrations. The disparity between apparent slope and maximum slope for 8% serum 
is detailed in Appendix Figure A-4. (c) Cell seeding density had an inverse relationship between 
contraction time and final assay area. Final contracted area is shown in mm2 and statistical differences 
are annotated on graphs in Appendix Figure A-6. 
in pixel intensity corresponds with degradation of the fibrin matrix. Initially, all conditions 
degraded fibrin at a similar rate; however, fibrinolysis slows down substantially with higher 
concentrations of TGF-β1 after the initial 12 hours. This timing corresponds with the 
increases in PAI-1 expression determined by qPCR in the previous section. Fibrin 
degradation initially proceeds at similar rates between conditions until the TGF-β1 
mediated increase in PAI-1 can establish an anti-fibrinolytic environment. Time-course 
evaluation of pixel intensity before contraction may therefore serve as an indicator for 
fibrin degradation.  
4.3.4 Evaluation of serum and cell number effects 
In order to validate remodeling behavior, the established stimuli of TGF-β1, serum, 
and cell seeding density were evaluated for their effects on matrix turnover. The 
relationship between contraction time and final contracted area of remodeled assays was 
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visualized using kernel density estimates to approximate probability density functions for 
each experimental condition. Figure 18A demonstrates the effects of TGF-β1 stimulation 
on the 50% contraction time and final area as determined in the previous section. With 
increasing concentrations of TGF-β1, the time for 50% contraction and the final assay area 
increased in a dose dependent manner. 
The effects of serum concentration on matrix remodeling were also evaluated. FBS 
contains a complex mix of growth factors, hormones, cytokines, proteases, zymogens, co-
factors, latent TGF-β1, and inhibitors that influence cellular activity. In the context of fibrin 
remodeling, one important component of FBS is plasminogen which can be activated by 
fibroblasts into plasmin for cell-mediated fibrinolysis. The fibroblast growth media used 
for propagating NHLF cells contained 2% FBS, but conditions were evaluated here ranging 
from serum-free to 8% serum content in the assay media.  
Serum free conditions did not contract within the length of the experiment, but there 
were slight changes in assay cross-sectional area over the course of the experiment. In the 
absence of serum, assays maintained their opaque appearance, indicating that very minimal 
fibrin degradation had occurred. Evaluation of contraction rate indicated no significant 
difference in contraction time for most conditions, however some replicates of the 8% 
condition contracted in multiple steps, resulting in larger values for 50% contraction time 
(Appendix Figure A-5). 
Final assay cross-sectional area exhibited dose-dependent increases in response to 
serum concentration, indicating increased deposition of collagen (Figure 18B). Due to the 
vast number of distinct proteins in serum, it is difficult to speculate which specific 
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components contribute to the altered assay remodeling. However, latent TGF-β1 and 
fibroblast growth factor (FGF) are both present in serum and have established effects on 
collagen production. These increases in concentration of serum are relevant to fibrotic 
disease. In vivo tissue availability of serum proteins depends largely on vascular 
permeability, and dysregulated endothelial permeability and vascular leak have long been 
associated with pulmonary fibrosis [217, 224].  
The initial fibroblast seeding density used to form assays is also relevant to IPF. 
Fibroblasts from fibrotic lungs have particularly proliferative phenotypes, resulting in 
higher numbers of fibroblasts and myofibroblasts in fibrotic tissue [235]. Here, initial 
fibroblast seeding density were varied between 1000 and 8000 cells/μl in order to evaluate 
the impact on remodeling (Figure 18C). Evaluation of contraction rate indicated significant 
dose dependent decreases in contraction time and increases in maximum contraction slope. 
Final assay cross-sectional area exhibited dose-dependent increases in response to higher 
cell density. The volume of cells within each assay contributes significantly to the final 
contracted assay size, so additional evaluation is necessary to determine differences in 
collagen deposition between conditions. Final volume of the contracted assay is dependent 
on a variety of contributors including cell number, ECM accumulation, and contractile 
stress. 
4.3.5 Fibroblast donor variability 
Alternative donors of normal and diseased fibroblasts were utilized in our assay to 
evaluate variability in remodeling behavior. Prior studies have demonstrated exaggerated  
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Figure 19. Consistency in response between cell lines: (a, b) Histologic sections show final 
contracted assays for NHLF B and IPF B with picrosirius red staining. For each example, color 
brightfield images are shown on the left with fluorescent images on the right. Scale bars are 250μm. 
(c-g) Individual plots for each fibroblast donor show remodeling response to TGF-β1 and nintedanib 
stimulation. (h) TGF-β1 response was compared between fibroblast donors with lines indicating the 
average responses with and without TGF-β1. Final areas are indicated in mm2 and statistical 
differences are annotated on graphs in Appendix Figure A-7. 
fibrogenic response in aged and diseased pulmonary fibroblasts compared to normal donors 
[197]. PAI-1 production and TGF signaling have both been implicated in this pathogenic 
alteration in behavior [10, 236]. We evaluated remodeling with pulmonary fibroblasts from 
2 normal donors, 2 IPF diseased donors, and one higher passage (p11) in order to evaluate 
consistency in assay progression. Each fibroblast lineage was evaluated with TGF-β1 to 
determine consistency in response to pro-fibrotic stimulus, in addition to nintedanib as an 
FDA-approved therapeutic. 
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Final contracted assays from normal and diseased fibroblasts were stained for 
histologic evaluation. These sections demonstrated consistency in organization of collagen 
in fluorescent images (Figure 19 A, B). However, PSR staining in color brightfield images 
had a darker hue in sections with IPF fibroblasts. It has previously been demonstrated that 
dysregulation of TGF-β1 signaling in diseased fibroblasts can contribute to increased 
activation of myofibroblasts in IPF [237]. It is possible that the altered hue of PSR staining 
in brightfield images reflects differences in contractility and compaction, but additional 
analysis is necessary to evaluate potential contributions. 
Evaluation of assay contraction time and final cross-sectional area demonstrated 
altered fibrin remodeling profiles between conditions (Figure 19 C-G). These shifts are 
particularly apparent in the response to TGF-β1, where IPF fibroblasts and high passage 
fibroblasts have a muted effect on final assay area (Figure 19H). These data indicate 
consistency in remodeling response to TGF-β1 and nintedanib between cell lineages, but 
magnitude of response to these stimuli varies between fibroblast donors.  
Prior studies have demonstrated increased sensitivity to TGF-β in diseased 
fibroblasts [10, 238], but TGF-β conditions in the fibrin remodelling assay had smaller 
final assay sizes compared to normal fibroblasts. Prior literature has also shown that 
diseased fibroblasts express more PAI-1, differentiate more easily into myofibroblasts, and 
synthesize more type I collagen [10, 197, 236]; however, both IPF fibroblasts and the 
higher passage number normal fibroblasts in this fibrin remodelling assay contracted into 
a smaller final assay size. This smaller final size may indicate decreased accumulation of 
collagen or greater contractility of cells within the assay. 
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Figure 20. Response to therapeutic stimuli: (a) Time-course changes in assay area show the 
effects of IPF therapeutics on remodelling behavior. (b) Evaluation with therapeutics targeting the 
fibrinolytic system demonstrate the impact of a PAI-1 inhibitor (TM 5275) and a tPA/uPA inhibitor 
(aprotinin). (c) Additional experimental therapeutics were also evaluated. Final areas are indicated in 
mm2 and statistical differences are annotated on graphs in Appendix Figure A-8. 
4.3.6 Drug response 
We then evaluated changes in remodeling with different therapeutic stimuli in order 
to assess applications as a pharmaceutical model of fibrotic disease. In IPF, specific sites 
of proliferative injury are identified as dense aggregates of ECM-producing fibroblasts, 
termed fibroblastic foci [17]. In clinical evaluation of IPF severity, the extent of fibroblastic 
foci within lung biopsies is used as a predictor of survival. Interestingly, the most important 
prognostic indicator from histologic analysis is the extent of young connective tissue 
present within the fibroblastic foci rather than the extent of interstitial cellularity or ECM 
accumulation [131]. Newly remodeled ECM is therefore a particularly important target for 
IPF therapeutic intervention. 
Here, we compared fibrin remodeling between healthy and diseased lung 
fibroblasts with a variety of stimulants (Figure 20). Ifenprodil was included as a potential 
IPF therapeutic that is currently being evaluated in clinical trials. Final assay area showed 
marginal increases compared to control in most conditions with one condition showing a 
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significant increase (Figure 20A). Ifenprodil inhibits lung fibroblast proliferation and 
differentiation, and has been shown to reverse the damage of initial acute lung injury in an 
animal model of pulmonary fibrosis [239]. While the mechanism for ifenprodil’s effects 
on fibrosis is not yet fully understood, current evidence indicates that it may play a role in 
reducing invasiveness of immune cells and fibroblasts [240, 241]. Ifenprodil may therefore 
act on aspects of fibrosis pathogenesis not evaluated in this assay. 
Nintedanib conditions showed significant decreases in final area for all conditions 
(P < 0.01). Nintedanib is a multiple tyrosine kinase inhibitor with effects on expression of 
ECM proteins and TGF-β1 induced signaling, so its tyrosine kinase inhibitory activity 
likely contributed to decreased final assay area through its effect on collagen production 
[242]. Stimulation with pirfenidone also demonstrated a significant decrease in fibrinolysis 
rate in most conditions (P < 0.01; except IPF TGF-β1−). The specific mechanism of 
pirfenidone is unclear, but it has been established to reduce fibroblast proliferation, α-SMA 
expression, and collagen synthesis [243, 244].  
Our prior assay for cell-mediated fibrinolysis did not show significant changes in 
fibrin degradation in response to nintedanib and pirfenidone, indicating minimal effects on 
the fibrinolytic system. By showing significant effects of these therapeutics on fibrinolysis, 
the fibrin remodelling assay demonstrated the utility of evaluating broader contributions to 
fibrosis. Nintedanib and pirfenidone are the two current FDA-approved therapeutics for 
IPF. In clinical use, administration of these drugs is incapable of halting or reversing 
fibrosis, and can only slow the spread of fibrotic scarring in the lungs [26]. The 
insufficiency of current IPF therapeutics served as motivation for development of this 
assay. 
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To address the need for alternative treatment strategies, several recent reviews have 
proposed components of the fibrinolytic system as potential targets for therapeutic 
intervention (Figure 20B) [214-216]. Inhibition of PAI-1 is of particular interest, as 
increased expression in IPF has been associated with worse clinical outcome [9, 10]. 
TM5275 is a small molecule inhibitor of PAI-1, which has been shown to minimize the 
extent of fibrotic remodeling in an animal model of pulmonary fibrosis [245]. Stimulation 
of assays with TM5275 decreased final assay size for all conditions, although these 
decreases were only statistically significant in the IPF condition without TGF-β1 (P < 
0.05). Interestingly, TM5275 was among the two drugs that demonstrated significant 
changes in contraction time (Appendix Figure A-8). This indicates that delays in start time 
of contraction may be related to inhibition of fibrinolysis by PAI-1.  
GLPG 1690 also demonstrated significant changes in contraction time (Appendix 
Figure A-8). This decreased time to contract may also be related to PAI-1 production. 
GLPG 1690 has been demonstrated to decrease TGF-β1-induced production of several pro-
fibrotic mediators in fibroblasts which are involved in PAI-1 production [246]. Final 
contracted area was also significantly decreased in all conditions treated with GLPG 1690. 
Diethyl-pythiDC is an inhibitor of prolyl 4-hydroxylase, which plays a role in post-
translational modifications that stabilize deposited collagen, and was included to evaluate 
the role of collagen matrix stability in remodeling of the assay [196]. However, prolyl 4-
hydroxylase is responsible for a variety of other post-translational modifications of proteins 
important to cell function, so there are multiple potential contributing pathways to the 
measured changes in assay remodling [202]. Alterations in PAI-1 expression may be also 
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be involved, but further evaluation of mRNA or protein expression would be necessary to 
confirm specific changes to the fibrinolytic system [199, 203]. 
Fibrosis is the aggregate outcome of diverse dysregulated contributions, and the 
readouts of this fibrin remodelling assay incorporate a broader variety of contributors than 
other current in vitro assays for fibrosis. A broad evaluation of protein and mRNA 
expression for components of each contributing pathway of the remodelling process would 
be necessary to fully understand which specific pathways cause changes to remodelling 
behaviour for a given set of conditions. This assay provides a pragmatic alternative by 
enabling phenotypic evaluation of the fibrinolytic system with high resolution time-course 
data for fibrin degradation. This enables visualization of the formation of fibrosis in vitro, 
resulting from the cumulative remodelling effects of fibrinolysis and collagen deposition.  
4.4 Conclusion 
Coordinated fibrinolysis and collagen deposition are necessary for restoration of 
tissue function after injury. However, no in vitro assays currently evaluate the combined 
effects of these processes on cell-mediated fibrin remodeling. Here, microscale fibroblast-
laden fibrin matrices were used to investigate the cumulative effects of fibrinolysis and 
collagen deposition on fibroblastic scar formation. By implementing ATPS printing of 
microscale fibrin scaffolds, we established an in vitro analogue to the provisional ECM In 
wound healing. This fibrin micro-scaffold was remodeled by fibroblasts through 
concurrent fibrinolysis and fibroplasia, followed by contraction. Through implementing 
and evaluating this assay, we demonstrated applications for an in vitro model for aberrant 
fibrin remodeling in evaluation of anti-fibrosis therapeutics. Despite different therapeutic 
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mechanisms, the assay was able to indicate changes in fibrotic remodeling with diverse 
therapeutic compounds at physiologically relevant concentrations.  
 Given the variety of contributors to dysregulation of fibrinolysis seen in fibrosis, 
cancer, and metabolic disease; this phenotypic assay provides a potentially valuable 
research tool for further studies in these fields. By mimicking matrix remodeling of the 
provisional fibrin matrix in vivo, this method offer a new approach to phenotypically 
evaluate fibrotic remodelling with applications in biological inquiry, personalized 






CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
 Dysregulation of fibrinolysis contributes to the pathogenesis of fibrosis, cancer, and 
metabolic disease; however, no prior assays have evaluated the phenotypic effects of 
dysregulated fibrinolysis on cell-mediated ECM remodeling. The microscale fibrin 
remodeling assay described in this dissertation provides a new research tool for label-free 
evaluation of fibroblast behavior within a fibrin scaffold, with a variety of applications in 
biomedical research and drug discovery. 
5.1 Conclusions 
5.1.1 Novel fibrin remodeling assay 
Fibrosis is the aggregate outcome of various dysregulated wound healing pathways. 
While wound healing is comprised of steps for initial epithelial damage, inflammation, 
proliferation, and remodeling; in vitro assays for fibrosis generally focus on quantifying 
specific proteins or mRNAs in a single stage of the remodeling process. In order to establish 
an assay that evaluates multifactorial contributions to the pathogenesis of fibrosis, this 
dissertation established a phenotypic assay for fibroblastic remodeling of microscale fibrin 
scaffolds. 
Here, we recapitulated certain aspects of the provisional fibrin matrix, which is 
present during the initial steps of wound healing. By culturing fibroblasts within a fibrin 
clot with physiologically relevant concentrations of serum and nutrients, fibroblasts are 
able to remodel the fibrin scaffold into a collagen-rich fibrous ECM. The work presented  
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Figure 21. Fibrinolysis assay vs. remodeling assay: Chapter 3 of this dissertation established 
an assay for cell-mediated fibrinolysis, where fibroblasts activated plasminogen into plasmin in order 
to degrade the fibrin scaffold. In Chapter 4 of this dissertation, modified culture conditions enabled 
concurrent fibrinolysis and collagen deposition, so that formation of fibrosis was visualized in vitro. 
here investigates the development and implementation of microscale fibrin scaffolds to 
assess cell-mediated fibrinolysis and remodeling. This required establishing a new 
approach to fabricate microscale fibrin scaffolds, which implemented aqueous two-phase 
printing for improved control over enzymatic crosslinking of fibrin. This offered 
unprecedented control over scaffold volume and cell seeding density for sub-microliter 
scaffolds, using standard liquid handling equipment. 
These micro-printed fibrin scaffolds were implemented as two separate assays 
(Figure 21). In the first assay, serum-free media and late addition of exogenous 
plasminogen enabled evaluation of cell-mediated fibrinolysis. This assay for cell-mediated 
fibrinolysis demonstrated our capability to evaluate changes to the fibrinolytic system 
through label free evaluation of brightfield images. However, evaluation of this assay with 
conventional IPF therapeutics showed no significant change in fibrin degradation with 
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established drugs. This demonstrated insufficiency of this assay in evaluating fibrosis, as 
well as insufficiency of IPF therapeutics at addressing contribution of fibrinolytic system 
to fibrosis. 
The second assay evaluated remodeling into collagen-dense fibrous matrix. Serum 
supplemented media in addition to a higher cell-seeding density and larger assay volume 
enabled concurrent fibrinolysis and collagen deposition (Figure 21).  With these modified 
conditions, the fibroblast-laden fibrin scaffold effectively formed a fibrotic mass that could 
be quantified as a readout of fibrosis. This readout demonstrated effects for a variety of 
therapeutic compounds with diverse mechanisms. These results illustrated that therapeutic 
stimuli targeted at fibrinolysis had an effect on fibrotic remodeling besides just their 
degradation of the fibrin matrix. Drugs that targeted the anti-fibrinolytic environment and 
persistence of the fibrin matrix resulted in altered collagenous remodeling that affected the 
final size of the contracted assay. These findings provide novel insight into the contribution 
of aberrant fibrinolysis on fibrotic remodeling, and this newly established experimental 
model can facilitate future in vitro studies of fibrotic remodeling. 
5.1.2 Context within the complexity of the lung 
Respiratory function requires maintenance of a complex biological environment 
that enables efficient gas exchange. Lung architecture is optimized to meet this demand 
through thin barrier membranes, substantial tissue elasticity, and a high surface area to 
volume ratio (Figure 22). In order to maintain this environment, various cell types are 
involved in coordinated remodeling processes that continually degrade and deposit 




Figure 22. Lung structure and cellular composition: (a) Lungs require significant structural 
organization in order to optimize gas exchange function. The hierarchical structures accomplish this 
through thin barrier membranes, substantial tissue elasticity, and a high surface area. (b) The 
provisional extracellular matrix forms following tissue damage, and contains substantial cellular 
heterogeneity. Immune cells include predominantly monocytes, macrophages, neutrophils, dendritic 
cells, and eosinophils. 
healthy tissue; however, several other cell types are involved in remodeling following 
tissue damage. During the wound repair process, differentiated myofibroblasts are 
predominantly responsible for ECM repair. These myofibroblasts can originate from 
circulating fibrocytes, epithelial cells (through epithelial mesenchymal transition), or 
resident interstitial cells [247]. The model system presented in this dissertation has 
exclusively been implemented with pulmonary interstitial fibroblasts. Due to heterogeneity 
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in remodeling behavior due to cell lineage and origin, the contribution of fibroblast and 
myofibroblasts to pathological remodeling varies by fibroblast source. 
 Airway epithelial cells also play a significant role in regulation of remodeling. In 
addition to their role in recovery of the epithelial layer after injury, epithelial cells use 
chemical and mechanical signaling to help coordinate activity of various growth factors 
and cytokines, including TGF-β1 [248]. The effects of epithelial regulation on remodeling 
by fibroblasts and myofibroblasts helps to minimize space occupied by the interstitial 
matrix, with the epithelial and endothelial basement membranes fusing together. This 
allows for minimal distance and efficient gas exchange across the alveolar–capillary barrier 
[249]. When epithelium is damaged, it initiates the coagulation cascade in addition to 
releasing pro-inflammatory and pro-fibrotic factors [250]. This environment recruits 
immune cells and fibroblasts to the injury site in order to initiate the wound healing process. 
Additionally, crosstalk between epithelium and fibroblasts regulates altered collagen 
production in wounded and diseased lungs [251]. Because the fibrin remodeling assay 
starts with a fibroblast-laden fibrin scaffold, it bypasses the steps of coagulation and 
cellular invasion. Altered initial conditions involving thrombin, fibrinogen, serum, or cell 
concentrations in the assay may replicate certain aspects of altered epithelial activity; 
however, inclusion of airway epithelial cells in the fibrin remodeling assay would be 
necessary to more fully evaluate the effects of their chemical and mechanical signaling on 
fibroblastic remodeling. 
Immune cells are also important in the remodeling of lung tissue due to their role 
in accommodating protection from infection and injury without considerably affecting 
tissue structure and function. Various cell types coordinate tissue repair responses that 
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entail inflammation for removal of potential threats, proper wound closure, and 
regeneration to maintain and restore healthy tissue. These cell types include monocytes, 
macrophages, neutrophils, dendritic cells, and eosinophils; which each have unique roles 
at certain stages of the wound healing process [252]. Activated macrophages play a 
particularly important role in remodeling due to their production of inflammatory cytokines 
and growth factors. Positive feedback loops between macrophages and fibroblasts promote 
augmented collagen production in wound healing and fibrosis [253]. By overlooking the 
effects of macrophages in our model, their contributions to the remodeling process are 
neglected. 
In vitro models necessarily simplify the cellular heterogeneity and micro-
environment from in vivo biological systems. In order to enable high-throughput 
adaptation, model systems must balance sophistication with ease of fabrication. By 
focusing specifically on fibroblast-mediated remodeling of fibrin, the assay developed in 
this thesis recapitulates aspects of wound healing related to fibrinolysis, collagen 
accumulation, and matrix contraction. Future implementations of this assay may 
incorporate additional cell types and modified microenvironments in order to address 
questions involving cellular interaction and mechanical feedback. However, in vitro assays 
will always neglect many of the interactions present in vivo. There are simply too many 
diverse feedback loops between cells, tissues, and organs. Animal models are also often 
insufficient to evaluate pathophysiology and therapeutic effects due to differences in 
enzymatic profiles and differences in pathologic mechanism in the animal model. Although 
the fibrin remodeling assay does provide convincing and intriguing results; specific 
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research question need to focus on mechanisms specific to fibroblast-matrix interactions 
and remodeling. 
5.1.3 Fibrin remodeling as a model for IPF 
Coordinated fibrinolysis and collagen deposition are necessary for restoration of 
tissue function after injury, and these processes are significantly dysregulated in IPF. The 
model system presented in this dissertation enables label-free phenotypic evaluation of the 
fibrin remodeling by fibroblasts. Despite the consensus that dysregulated coagulation and 
fibrinolysis contribute to IPF pathogenesis, current FDA-approved therapies have no 
significant effect on regulation of fibrinolysis [254, 255]. 
The fibrin remodeling assay enables specific questions about fibroblast-mediated 
fibrinolysis and collagen deposition in the fibrin-rich provisional ECM. Our fibrinolysis 
assay from Chapter 3 demonstrated that the IPF therapeutics nintedanib and pirfenidone 
have no significant effects on fibrin degradation. Then, in Chapter 4 we demonstrated that 
stimuli targeting the fibrinolytic system can have a significant impact on fibrosis formation. 
This approach of phenotypically evaluating drug effects on fibrin remodeling enabled 
demonstration of significant decreases in fibrotic remodeling with significantly lower 
concentrations of pirfenidone than prior studies. However, the drug ifenprodil still showed 
no significant effects on remodeling. This therapeutic is currently in stage 3 clinical trials, 
showing promising effects on IPF patients. Prior studies indicate that systemic interactions 
or crosstalk with other cell types may be responsible for ifenprodil’s mechanism in IPF. 
Demonstrating remodeling effects with ifenprodil may therefore require a more 
sophisticated in vitro model in order to demonstrate its effects. 
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Future implementations of this fibrin remodeling assay may focus on enabling other 
cell types to contribute to therapeutic effects. In particular, alveolar epithelial cells and 
alveolar macrophages play an important role in IPF pathogenesis. The epithelium acts as 
both a physical and immunological barrier against the environment, but dysregulated 
epithelial cells in the IPF lung experience loss of barrier permeability and injury in the 
absence of external stimulus. This altered behavior affects cytokine production, 
inflammation, and myofibroblast activation in the fibrotic lung [250]. In addition to 
dysregulated epithelium, overactive macrophages in IPF have demonstrated excessive 
expression of inflammatory cytokines and growth factors. This creates a positive feedback 
loop between macrophages and fibroblasts, resulting in increased collagen production 
[253]. Drug effects on epithelial cells and macrophages are therefore an important 
consideration in evaluating IPF therapeutics. 
While most drugs evaluated in Chapter 4 demonstrated altered remodeling activity 
with only fibroblasts, many of these compounds have established effects on other cell 
types. Nintedanib and pirfenidone have both been shown to minimize epithelial to 
mesenchymal transition in small airway epithelium and reduce the production of 
inflammatory cytokines in macrophages [256-259]. Other compounds from Chapter 4 have 
similarly demonstrated therapeutic effects on cell types besides their remodeling effects on 
fibroblasts and myofibroblasts. Co-culture adaptations of this fibrin remodeling assay may 
integrate epithelial cells or macrophages in order to more broadly evaluate additional 
contributions to fibrotic remodeling in IPF. 
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5.2 Future Directions 
5.2.1 High-Throughput Screening for COVID-19 Therapeutics 
Findings from this thesis have already been used to support application of this assay to 
evaluate potential COVID-19 therapeutics. The pathophysiology of SARS-COV 2 is still 
largely unknown, but fibrin remodeling appears to play a major role in resolution of severe 
infections. Damage to alveolar epithelial cells by SARS-COV 2 and accompanying 
bacterial infection cause edema and subsequent coagulation to form fibrin clots in the lungs 
[260]. This can create a positive feedback cycle of fibrin formation, myobroblast activation, 
collagen production, and stiffening of the lungs that can cause additional epithelial damage. 
By implementing this assay to find therapeutics that minimize fibrotic remodeling of fibrin, 
we may be able to suggest prophylactic drugs that lessen the extent of damage during 
severe stages of COVID-19. Our efforts to evaluate FDA drug libraries for fibroblastic 
remodeling may help determine therapies that can help improve remodeling of fibrin clots 
in the lungs to minimize permanent damage in the lungs. 
However, fibrin remodeling is only a small aspect of COVID-19 pathogenesis. 
Immune response is vital to clearance of the virus, and persistence of the fibrin matrix may 
play a role in containing immune cells as they fight the virus. Additionally, non-plasmin 
signaling of the fibrinolytic system may be involved in generation of the cytokine storm 
[261]. An overly fibrinolytic environment could therefore inadvertently contribute to 
increases in inflammatory cytokines, with potentially damaging systemic effects. 
Other important aspects of covid-19 pathogenesis are beyond the scope of this 
assay. Questions involving differences in immune response, severity of cytokine storm, 
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and development of systemic damage require alternative model systems for evaluation. 
Other in vitro models, animal models, and human data are necessary to address these 
unanswered questions regarding COVID-19 pathogenesis and treatment. 
5.2.2 Evalution of Nox4 Inhibitor for IPF 
Our lab also has an ongoing grant to evaluate a novel Nox4 inhibitor for its effects 
on fibrotic remodeling with in vitro models of fibrosis. Both direct and indirect 
mechanisms linking reactive oxygen species and TGF-β1 pathways have been identified 
as potential pathogenic contributors in IPF; however, no current IPF therapeutics use this 
as a target [262]. Additionally, these pathways target some of the age-specific changes in 
ROS metabolism that correlate with IPF. Preliminary experiments with hydrogen peroxide 
in our cell-mediated fibrinolysis indicated that fibrin degradation in our system is sensitive 
to ROS, so we hope to see alleviations in fibrotic remodeling in response to this novel Nox4 
inhibitor. This application may require adaptations of the fibrin remodeling assay that 
evaluate remodeling over longer periods of time. Dynamic culture conditions may also be 
implemented to evaluate interventional therapy that is introduced after assays are already 
on a pathogenic trajectory. 
5.2.3 Co-culture models 
In order to evaluate additional contributors to the multifactorial process of ECM 
remodeling of the lungs, it will be interesting to evaluate co-culture models in this assay. 
In particular, epithelial cells and macrophages have been shown to alter fibroblast 
phenotypes in the context of fibrotic remodeling. Preliminary experiments with small 
airway epithelial cells in the fibrin scaffolds demonstrated immediate fibrin degradation 
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regardless of stimulus. Endothelial cells are known to be particularly pro-fibrinolytic, 
producing high amounts of tPA [263]. Future adaptations of this experiment may add 
different amount of intact or damaged epithelial cells to fibroblast-laden assays in order to 
evaluate contributions of epithelium and damaged epithelium to fibrotic remodeling. 
Macrophages will also be included in co-culture assays in order to evaluate the effects of 
macrophage-secreted factors on remodeling. However, in sophisticated co-culture models, 
the additional elements of variability can make assay results more difficult to interpret. In 
order to differentiate between conditions, these models need to be geared towards specific 
questions. Co-culture models may be uniquely geared towards evaluating cellular invasion, 
differentiation, and synergistic drug effects involving positive feedback mechanisms or 
crosstalk. Future adaptations of fibrin remodeling assays may introduce unique capabilities 
which can address unanswered questions about fibrosis pathogenesis and treatment. 
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APPENDIX A. SUPPLEMENTAL INFORMATION 
A.1  Supplemental fibrinolysis 
 
 
Appendix Figure A-1. Brightness correction for live cell imaging: The Incucyte S3 (Essen 
Biosystems) automatically adjusts image brightness to maintain white balance, with no 
option to manually fix the relevant settings. In order to compensate for this automated 
adjustment of images, brightfield micrographs were re-scaled so that the background was 
consistent between images. This adjustment was necessary for the volume evaluation in 
Figure 12. Here, upper images show original brightfield and lower images show 
adjustments made using an automated script in Python 3. These corrected images were 






Appendix Figure A-2. Comparison of control conditions: Overlapping conditions from 
different experiments were compared according to cell passage number. All assays shown 
used 1 μl of fibrin with 1000 fibroblasts and plasminogen added at 24 hours, with no 
additional stimuli. Respective conditions come from IPF therapeutic comparison in Figure 
14 (IPF p5), TGF-β1 response in Figure 13 (NHLF p3), NHLF therapeutic comparison in 
Figure 14 (NHLF p5), cell number effect in Figure 13 (NHLF p6), plasminogen timing in 
Figure 11 (NHLF p12P), and volume consistency in Figure 12 (NHLF p12V). Passage 
numbers were compared by time-course pixel intensity (a) and time to 50% degradation 







Appendix Figure A-3. Description of Supplemental Video 1 - Fibrinolysis: This video 
demonstrates degradation of fibroblast-laden fibrin scaffolds with plasmin and 
plasminogen added at 24 hours. With active plasmin, the matrix degrades almost 
immediately; however, plasminogen is delayed due to the necessity for plasminogen to be 
activated by cellular activity. Graphs below each micrograph illustrate changes in average 
pixel intensity as determined by our automated image processing approach. Micrographs 





A.2  Supplemental ECM remodeling 
 
Appendix Figure A-4. Area validation and time-course pixel intensity: (a) In order to 
validate the automated output from the assay mask generator, final assay sizes were 
compared between the automated image processing approach and ImageJ. This comparison 
showed no significant differences between alternate determinations of final contracted 
assay area. (b) Leading up to contraction, image brightness within the masked region was 
evaluated for different TGF-β1 concentrations. While initial slopes appeared similar 






Appendix Figure A-5. Multi-step contraction and double sigmoid fit: Many conditions 
with higher concentrations of TGF-β1 or serum contracted in a multi-step process. (a) The 
single sigmoid had relatively low R2 values, so an alternative approach (b) using a double 










Appendix Figure A-6. Serum concentration and seeding density effects: (a, b) Time-
course changes in assay area show the effects on assay contraction of FBS concentration 
on the left and fibroblast seeding density on the right. Fitting of sigmoidal functions to each 
experimental replicate enabled extraction of 50% contraction time (in days) (c, f) and 
maximum slope (d, g). Note that the disparity between apparent slope and maximum slope 
for 8% serum (a, d) is detailed in Appendix Figure A-2. (e, h) Final contracted area was 
also determined for each condition, shown in mm2. (Statistical significance:  ab, bc, ef = P 









Appendix Figure A-7. Consistency in response between cell lines: (a, b) Histologic 
sections show final contracted assays for NHLF B and IPF B with picrosirius red staining. 
For each example, color brightfield images are shown on the left with fluorescent images 
on the right. Scale bars are 250μm. Time-course changes in assay area show the effects of 
cell line variability on assay contraction with no TGF-β1 (c) and with 2 ng/ml TGF-β1 (d). 
Dotted lines indicate conditions with the IPF therapeutic nintedanib. (e, f) Final contracted 







Appendix Figure A-8. Response to therapeutic stimuli: (a, b) Time-course changes in 
assay area show the effects of various therapeutic stimuli on NHLF (left) and IPF 
fibroblasts (right) in the absence of TGF-β1. (c, d) Parallel conditions to the upper graphs 
show the effects of these therapeutics with addition of 2 ng/ml TGF-β1. (e, f) Final 
contracted area was also determined for each condition, indicated in mm2. (Statistical 





Appendix Figure A-9. Description of Supplemental Video 2 – ECM Remodeling: This 
video demonstrates altered remodeling of fibroblast laden fibrin scaffolds with different 
concentrations of TGF-β1. Higher concentrations result in delayed contraction and larger 
final size of the contracted matrix. Graphs below each micrograph demonstrate the image 
processing output of area masks for each time point. Micrographs were taken by the 
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